index,review_code,title
0,CD000011,CD000011 v. 10.0 Interventions for enhancing medication adherence
1,CD000012,CD000012 v. 10.0 Alternative versus conventional institutional settings for birth
2,CD000024,CD000024 v. 9.1 Anticoagulants for acute ischaemic stroke
3,CD000025,CD000025 v. 10.0 Magnesium sulphate and other anticonvulsants for women with pre-eclampsia
4,CD000028,CD000028 v. 16.0 Pharmacotherapy for hypertension in adults 60 years or older
5,CD000029,CD000029 v. 9.19 Oral antiplatelet therapy for acute ischaemic stroke
6,CD000031,CD000031 v. 21.3 Antidepressants for smoking cessation
7,CD000033,CD000033 v. 9.12 Barbiturates for acute traumatic brain injury
8,CD000057,CD000057 v. 7.0 Clomiphene citrate for unexplained subfertility in women
9,CD000081,CD000081 v. 9.0 Selective versus routine use of episiotomy for vaginal birth
10,CD000084,CD000084 v. 8.0 External cephalic version for breech presentation before term
11,CD000093,CD000093 v. 9.200 Cephalomedullary nails versus extramedullary implants for extracapsular hip fractures in older adult
12,CD000099,CD000099 v. 7.139 Growth hormone for in vitro fertilisation (IVF)
13,CD000103,CD000103 v. 5.0 Haemodilution for acute ischaemic stroke
14,CD000110,CD000110 v. 7.0 Hospitalisation and bed rest for multiple pregnancy
15,CD000126,CD000126 v. 7.9 Local versus general anaesthesia for carotid endarterectomy
16,CD000146,CD000146 v. 22.0 Nicotine replacement therapy versus control for smoking cessation
17,CD000165,CD000165 v. 14.0 Physician advice for smoking cessation
18,CD000169,CD000169 v. 19.2 Drugs for preventing malaria in pregnant women in endemic areas any drug regimen versus placebo or 
19,CD000198,CD000198 v. 13.0 Support during pregnancy for women at increased risk of low birthweight babies
20,CD000208,CD000208 v. 12.0 Miscellaneous treatments for antipsychotic-induced tardive dyskinesia
21,CD000214,CD000214 v. 11.0 Training health professionals in smoking cessation
22,CD000227,CD000227 v. 12.1 Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men
23,CD000230,CD000230 v. 9.104 Zinc supplementation for improving pregnancy and infant outcome
24,CD000253,CD000253 v. 19.0 Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
25,CD000254,CD000254 v. 16.0 Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degen
26,CD000259,CD000259 v. 11.2 Audit and feedback effects on professional practice and healthcare outcomes
27,CD000265,CD000265 v. 15.0 Compression for venous leg ulcers
28,CD000280,CD000280 v. 8.0 Carbohydrate supplementation of human milk to promote growth in preterm infants
29,CD000307,CD000307 v. 10.0 Fluphenazine decanoate (depot) and enanthate for schizophrenia
30,CD000313,CD000313 v. 9.10 Discharge planning from hospital
31,CD000323,CD000323 v. 9.0 Swallowing therapy for dysphagia in acute and subacute stroke
32,CD000331,CD000331 v. 11.0 Epidural versus non-epidural or no analgesia for pain management in labour
33,CD000333,CD000333 v. 9.0 Exercise for preventing and treating osteoporosis in postmenopausal women
34,CD000360,CD000360 v. 10.0 Assisted reproductive technologies for male subfertility
35,CD000371,CD000371 v. 20.0 Public health deworming programmes for soil-transmitted helminths in children living in endemic area
36,CD000384,CD000384 v. 8.2 Length of hospitalisation for people with severe mental illness
37,CD000398,CD000398 v. 8.0 Nitric oxide donors (nitrates) L-arginine or nitric oxide synthase inhibitors for acute stroke
38,CD000422,CD000422 v. 8.0 Vaccines for preventing pneumococcal infection in adults
39,CD000425,CD000425 v. 9.0 Speech and language therapy for aphasia following stroke
40,CD000434,CD000434 v. 13.5 Interventions for treating proximal humeral fractures in adults
41,CD000478,CD000478 v. 7.0 Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis
42,CD000490,CD000490 v. 8.0 Antibiotics for asymptomatic bacteriuria in pregnancy
43,CD000494,CD000494 v. 11.0 Prostaglandins for preventing postpartum haemorrhage
44,CD000515,CD000515 v. 7.0 Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis
45,CD000521,CD000521 v. 10.0 Anaesthesia for hip fracture surgery in adults
46,CD000526,CD000526 v. 8.2 Interventions for treating tuberculous pericarditis
47,CD000530,CD000530 v. 11.0 Echinacea for preventing and treating the common cold
48,CD000553,CD000553 v. 7.0 Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention
49,CD000567,CD000567 v. 16.12 Colloids versus crystalloids for fluid resuscitation in critically ill people
50,CD000934,CD000934 v. 9.0 Alternative versus standard packages of antenatal care for low-risk pregnancy
51,CD000963,CD000963 v. 9.3 Multidisciplinary biopsychosocial rehabilitation for chronic low back pain
52,CD000978,CD000978 v. 14.2 Interventions for preventing oral mucositis for patients with cancer receiving treatment
53,CD000979,CD000979 v. 7.16 Orthodontic treatment for posterior crossbites
54,CD000984,CD000984 v. 11.0 Interventions to change the behaviour of health professionals and the organisation of care to promot
55,CD000990,CD000990 v. 10.0 Exercise for intermittent claudication
56,CD000994,CD000994 v. 9.4 Home care by outreach nursing for chronic obstructive pulmonary disease
57,CD001000,CD001000 v. 13.0 Corticosteroids for the prevention and treatment of post-extubation stridor in neonates children an
58,CD001007,CD001007 v. 9.68 Group behaviour therapy programmes for smoking cessation
59,CD001019,CD001019 v. 7.0 Oral contraceptives for pain associated with endometriosis
60,CD001021,CD001021 v. 13.12 Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis
61,CD001023,CD001023 v. 6.0 Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haem
62,CD001035,CD001035 v. 9.0 Interventions for encouraging sexual behaviours intended to prevent cervical cancer
63,CD001055,CD001055 v. 10.0 Psychosocial interventions for supporting women to stop smoking in pregnancy
64,CD001067,CD001067 v. 11.0 Antibiotic regimens for postpartum endometritis
65,CD001069,CD001069 v. 9.0 Sucrose for analgesia in newborn infants undergoing painful procedures
66,CD001088,CD001088 v. 11.2 Psychosocial interventions for people with both severe mental illness and substance misuse
67,CD001118,CD001118 v. 13.0 Print-based self-help interventions for smoking cessation
68,CD001120,CD001120 v. 8.0 Reminiscence therapy for dementia
69,CD001122,CD001122 v. 14.0 Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syn
70,CD001134,CD001134 v. 9.0 Psychosocial and psychological interventions for preventing postpartum depression
71,CD001139,CD001139 v. 7.0 Interventions for preventing and treating low-back and pelvic pain during pregnancy
72,CD001141,CD001141 v. 11.6 Support for healthy breastfeeding mothers with healthy term babies
73,CD001168,CD001168 v. 7.0 Interventions for treating oral lichen planus corticosteroid therapies
74,CD001174,CD001174 v. 5.0 Manually-generated reminders delivered on paper effects on professional practice and patient outcom
75,CD001175,CD001175 v. 7.0 Computer-generated reminders delivered on paper to healthcare professionals effects on professional
76,CD001188,CD001188 v. 11.0 Nursing interventions for smoking cessation
77,CD001191,CD001191 v. 19.0 Rivastigmine for Alzheimer's disease
78,CD001206,CD001206 v. 13.0 Pharmacotherapy for social anxiety disorder (SAnD)
79,CD001218,CD001218 v. 11.0 Acupuncture for the prevention of episodic migraine
80,CD001233,CD001233 v. 9.10 Mechanical methods for induction of labour
81,CD001245,CD001245 v. 11.4 Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
82,CD001255,CD001255 v. 15.2 Hip protectors for preventing hip fractures in older people
83,CD001256,CD001256 v. 9.0 Interventions for preventing lower limb soft-tissue running injuries
84,CD001269,CD001269 v. 17.0 Vaccines for preventing influenza in healthy adults
85,CD001271,CD001271 v. 7.0 Nurses as substitutes for doctors in primary care
86,CD001277,CD001277 v. 12.0 Breathing exercises for adults with asthma
87,CD001287,CD001287 v. 13.0 Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease
88,CD001291,CD001291 v. 9.0 Community interventions for preventing smoking in young people
89,CD001292,CD001292 v. 9.0 Individual behavioural counselling for smoking cessation
90,CD001293,CD001293 v. 13.0 School-based programmes for preventing smoking
91,CD001298,CD001298 v. 12.0 Fluid and pharmacological agents for adhesion prevention after gynaecological surgery
92,CD001301,CD001301 v. 11.6 Intracytoplasmic sperm injection versus conventional in vitro fertilisation in couples with males pr
93,CD001321,CD001321 v. 18.121 Cranberries for preventing urinary tract infections
94,CD001337,CD001337 v. 7.140 Umbilical vein injection for management of retained placenta
95,CD001347,CD001347 v. 9.0 Bisphosphonates for steroid-induced osteoporosis
96,CD001392,CD001392 v. 10.0 Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults
97,CD001395,CD001395 v. 7.0 Phytoestrogens for menopausal vasomotor symptoms
98,CD001408,CD001408 v. 5.0 Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy
99,CD001417,CD001417 v. 16.8 Topiramate add-on therapy for drug-resistant focal epilepsy
100,CD001423,CD001423 v. 12.22 Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement
101,CD001430,CD001430 v. 12.1 Corticosteroids for treating optic neuritis
102,CD001431,CD001431 v. 12.0 Decision aids for people facing health treatment or screening decisions
103,CD001451,CD001451 v. 9.0 Routine ultrasound in late pregnancy (after 24 weeks' gestation)
104,CD001457,CD001457 v. 9.0 Glutamine supplementation to prevent morbidity and mortality in preterm infants
105,CD001479,CD001479 v. 12.0 Vitamin A for treating measles in children
106,CD001480,CD001480 v. 15.0 Pneumococcal conjugate vaccines for preventing acute otitis media in children
107,CD001511,CD001511 v. 7.2 Glucocorticosteroids for people with alcoholic hepatitis
108,CD001533,CD001533 v. 15.0 Corticosteroid therapy for nephrotic syndrome in children
109,CD001538,CD001538 v. 12.0 Surgery for nonarteritic anterior ischemic optic neuropathy
110,CD001546,CD001546 v. 8.2 Laparoscopic versus open surgery for suspected appendicitis
111,CD001688,CD001688 v. 7.0 Interventions for promoting the initiation of breastfeeding
112,CD001704,CD001704 v. 10.7 Interventions for improving mobility after hip fracture surgery in adults
113,CD001730,CD001730 v. 6.0 Medical day hospital care for older people versus alternative forms of care
114,CD001746,CD001746 v. 9.0 Family and carer smoking control programmes for reducing children's exposure to environmental tobacc
115,CD001750,CD001750 v. 11.0 Gonadotrophin-releasing hormone antagonists for assisted reproductive technology
116,CD001751,CD001751 v. 7.0 Nonsteroidal anti-inflammatory drugs for dysmenorrhoea
117,CD001754,CD001754 v. 9.0 Traditional suburethral sling operations for urinary incontinence in women
118,CD001756,CD001756 v. 11.0 Mechanical devices for urinary incontinence in women
119,CD001781,CD001781 v. 12.0 Topical treatments for cutaneous warts
120,CD001800,CD001800 v. 15.11 Exercise-based cardiac rehabilitation for coronary heart disease
121,CD001822,CD001822 v. 12.1 Physical conditioning as part of a return to work strategy to reduce sickness absence for workers wi
122,CD001829,CD001829 v. 8.2 Interventions for treating oral leukoplakia to prevent oral cancer
123,CD001830,CD001830 v. 7.2 Pit and fissure sealants for preventing dental decay in permanent teeth
124,CD001838,CD001838 v. 11.0 Intra-uterine insemination for unexplained subfertility
125,CD001841,CD001841 v. 8.0 First-line drugs for hypertension
126,CD001843,CD001843 v. 11.0 Conservative management for postprostatectomy urinary incontinence
127,CD001860,CD001860 v. 11.0 Antibiotics for trachoma
128,CD001865,CD001865 v. 8.4 Personalised risk communication for informed decision making about taking screening tests
129,CD001867,CD001867 v. 11.0 Opioid antagonists for alcohol dependence
130,CD001871,CD001871 v. 15.2 Interventions for preventing obesity in children
131,CD001877,CD001877 v. 12.0 Screening for breast cancer with mammography
132,CD001880,CD001880 v. 11.0 Nutritional supplementation for hip fracture aftercare in older people
133,CD001884,CD001884 v. 6.0 Desmopressin use for minimising perioperative blood transfusion
134,CD001893,CD001893 v. 10.3 Epidural local anaesthetics versus opioid-based analgesic regimens for postoperative gastrointestina
135,CD001919,CD001919 v. 7.178 Information provision for stroke survivors and their carers
136,CD001920,CD001920 v. 6.9 Physical rehabilitation approaches for the recovery of function and mobility following stroke
137,CD001929,CD001929 v. 12.12 Massage for low-back pain
138,CD001951,CD001951 v. 7.0 Haloperidol dose for the acute phase of schizophrenia
139,CD001955,CD001955 v. 15.8 Glucocorticoids for croup in children
140,CD001973,CD001973 v. 9.0 Interventions for treating oral mucositis for patients with cancer receiving treatment
141,CD001977,CD001977 v. 8.0 Acupuncture for peripheral joint osteoarthritis
142,CD001980,CD001980 v. 8.0 Mind and body therapy for fibromyalgia
143,CD002003,CD002003 v. 13.3 Beta-blockers for hypertension
144,CD002008,CD002008 v. 11.1 Dietary advice with or without oral nutritional supplements for disease-related malnutrition in adul
145,CD002011,CD002011 v. 8.102 Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis
146,CD002014,CD002014 v. 8.0 Behavioural treatment for chronic low-back pain
147,CD002018,CD002018 v. 7.3 Antidepressant treatment for postnatal depression
148,CD002020,CD002020 v. 12.0 Group-based parent training programmes for improving parental psychosocial health
149,CD002025,CD002025 v. 14.0 Buprenorphine for managing opioid withdrawal
150,CD002042,CD002042 v. 11.0 Transfusion thresholds for guiding red blood cell transfusion
151,CD002053,CD002053 v. 6.10 Sedatives for opioid withdrawal in newborn infants
152,CD002059,CD002059 v. 7.6 Opioid treatment for opioid withdrawal in newborn infants
153,CD002097,CD002097 v. 7.0 Primary care professionals providing non-urgent care in hospital emergency departments
154,CD002098,CD002098 v. 6.0 Interactive telemedicine effects on professional practice and health care outcomes
155,CD002114,CD002114 v. 11.0 Weighted vaginal cones for urinary incontinence
156,CD002120,CD002120 v. 6.51 Combined oral contraceptive pill for primary dysmenorrhoea
157,CD002124,CD002124 v. 6.0 Dietary supplements for dysmenorrhoea
158,CD002137,CD002137 v. 9.0 Reduced or modified dietary fat for preventing cardiovascular disease
159,CD002140,CD002140 v. 7.0 Concurrent chemoradiotherapy in non-small cell lung cancer
160,CD002141,CD002141 v. 11.0 Drugs for preventing lung cancer in healthy people
161,CD002142,CD002142 v. 15.0 Postoperative radiotherapy for non-small cell lung cancer
162,CD002143,CD002143 v. 14.2 Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer
163,CD002193,CD002193 v. 8.150 Multidisciplinary biopsychosocial rehabilitation for subacute low back pain
164,CD002200,CD002200 v. 7.6 Follow-up strategies for patients treated for non-metastatic colorectal cancer
165,CD002202,CD002202 v. 13.15 Hydroxyurea (hydroxycarbamide) for sickle cell disease
166,CD002213,CD002213 v. 8.2 Interprofessional education effects on professional practice and healthcare outcomes
167,CD002229,CD002229 v. 15.0 Hormone therapy for preventing cardiovascular disease in post-menopausal women
168,CD002244,CD002244 v. 8.1 Corticosteroids for managing tuberculous meningitis
169,CD002249,CD002249 v. 7.0 Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome
170,CD002250,CD002250 v. 8.0 Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes an
171,CD002251,CD002251 v. 11.0 Techniques for preventing hypotension during spinal anaesthesia for caesarean section
172,CD002252,CD002252 v. 10.0 Antihypertensive drug therapy for mild to moderate hypertension during pregnancy
173,CD002253,CD002253 v. 8.0 Medical treatment for early fetal death (less than 24 weeks)
174,CD002283,CD002283 v. 6.7 Retention procedures for stabilising tooth position after treatment with orthodontic braces
175,CD002290,CD002290 v. 13.0 Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in childre
176,CD002292,CD002292 v. 13.258 Interventions for bullous pemphigoid
177,CD002294,CD002294 v. 10.0 Interventions for preoperative smoking cessation
178,CD002295,CD002295 v. 11.5 Exercise interventions for smoking cessation
179,CD002302,CD002302 v. 5.0 Pressure-relieving interventions for treating diabetic foot ulcers
180,CD002309,CD002309 v. 10.6 Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease
181,CD002752,CD002752 v. 10.0 Disease management interventions for heart failure
182,CD002768,CD002768 v. 18.4 Physical activity and exercise training in cystic fibrosis
183,CD002779,CD002779 v. 7.0 Interventions for treating burning mouth syndrome
184,CD002783,CD002783 v. 9.114 Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower 
185,CD002785,CD002785 v. 6.0 Chelation therapy for atherosclerotic cardiovascular disease
186,CD002786,CD002786 v. 6.10 Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts
187,CD002795,CD002795 v. 9.9 Pharmacotherapy for post traumatic stress disorder (PTSD)
188,CD002829,CD002829 v. 8.0 Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease
189,CD002834,CD002834 v. 8.85 Interventions targeted at women to encourage the uptake of cervical screening
190,CD002840,CD002840 v. 7.0 Treadmill training and body weight support for walking after stroke
191,CD002843,CD002843 v. 6.0 Strategies for partner notification for sexually transmitted infections including HIV
192,CD002850,CD002850 v. 12.0 Telephone counselling for smoking cessation
193,CD002854,CD002854 v. 10.1 Vitamin E for Alzheimer's dementia and mild cognitive impairment
194,CD002855,CD002855 v. 9.6 Medical methods for first trimester abortion
195,CD002878,CD002878 v. 8.19 Chronic non-invasive ventilation for chronic obstructive pulmonary disease
196,CD002892,CD002892 v. 10.18 Individual-level interventions for reducing occupational stress in healthcare workers
197,CD002902,CD002902 v. 11.0 Psychological interventions for coronary heart disease
198,CD002911,CD002911 v. 9.0 Alarm interventions for nocturnal enuresis in children
199,CD002922,CD002922 v. 10.0 Immunosuppressive treatment for proliferative lupus nephritis
200,CD002947,CD002947 v. 7.0 Oral herbal therapies for treating osteoarthritis
201,CD002962,CD002962 v. 10.0 Acupuncture or acupressure for induction of labour
202,CD002971,CD002971 v. 10.0 Formula versus donor breast milk for feeding preterm or low birth weight infants
203,CD002990,CD002990 v. 18.5 Self-management interventions for people with chronic obstructive pulmonary disease
204,CD002991,CD002991 v. 10.5 Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease
205,CD003002,CD003002 v. 9.4 Drug therapy for obstructive sleep apnoea in adults
206,CD003006,CD003006 v. 10.0 Transient neurological symptoms (TNS) following spinal anaesthesia with lidocaine versus other local
207,CD003010,CD003010 v. 9.0 Traction for low-back pain with or without sciatica
208,CD003018,CD003018 v. 6.2 Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5
209,CD003020,CD003020 v. 12.0 Universal school-based prevention for illicit drug use
210,CD003030,CD003030 v. 7.0 Continuing education meetings and workshops effects on professional practice and healthcare outcome
211,CD003031,CD003031 v. 9.13 Prophylactic drug management for febrile seizures in children
212,CD003034,CD003034 v. 10.0 Techniques for the interruption of tubal patency for female sterilisation
213,CD003036,CD003036 v. 11.0 Immediate postpartum insertion of intrauterine device for contraception
214,CD003048,CD003048 v. 7.4 Probiotics for treating acute infectious diarrhoea
215,CD003053,CD003053 v. 12.0 Insulin-sensitising drugs (metformin rosiglitazone pioglitazone D-chiro-inositol) for women with 
216,CD003054,CD003054 v. 6.2 Diet physical activity or both for prevention or delay of type 2 diabetes mellitus and its associat
217,CD003079,CD003079 v. 9.6 Benzodiazepines for psychosis-induced aggression or agitation
218,CD003086,CD003086 v. 10.2 Opioid antagonists for smoking cessation
219,CD003091,CD003091 v. 9.2 Dressings for the prevention of surgical site infection
220,CD003130,CD003130 v. 6.4 Mobile bearing vs fixed bearing prostheses for posterior cruciate retaining total knee arthroplasty 
221,CD003137,CD003137 v. 11.0 Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chron
222,CD003146,CD003146 v. 13.0 Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease
223,CD003148,CD003148 v. 8.0 Psychological interventions for individuals with cystic fibrosis and their families
224,CD003150,CD003150 v. 9.0 Aromatherapy for dementia
225,CD003154,CD003154 v. 15.0 Memantine for dementia
226,CD003171,CD003171 v. 6.32 Surgical interventions for bilateral congenital cataract in children aged two years and under
227,CD003175,CD003175 v. 7.0 Adjuvant chemotherapy for endometrial cancer after hysterectomy
228,CD003177,CD003177 v. 10.4 Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
229,CD003179,CD003179 v. 5.2 Adrenaline and vasopressin for cardiac arrest
230,CD003193,CD003193 v. 7.0 Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrom
231,CD003200,CD003200 v. 33.0 Exercise therapy for chronic fatigue syndrome
232,CD003212,CD003212 v. 9.10 Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pre
233,CD003214,CD003214 v. 9.0 Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants
234,CD003220,CD003220 v. 7.2 Pulp treatment for extensive decay in primary teeth
235,CD003232,CD003232 v. 10.2 Interventions for renal vasculitis in adults
236,CD003233,CD003233 v. 10.1 Interventions for focal segmental glomerulosclerosis in adults
237,CD003236,CD003236 v. 7.0 Exercise training for adults with chronic kidney disease
238,CD003248,CD003248 v. 9.0 Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion 
239,CD003249,CD003249 v. 9.0 Treatment for primary postpartum haemorrhage
240,CD003262,CD003262 v. 11.7 Interventions for rosacea
241,CD003263,CD003263 v. 13.0 Interventions for vitiligo
242,CD003267,CD003267 v. 7.2 Interventions for providers to promote a patient-centred approach in clinical consultations
243,CD003277,CD003277 v. 17.27 Anti-seizure medications for Lennox-Gastaut syndrome
244,CD003281,CD003281 v. 8.0 Stimulation of the wrist acupuncture point PC6 for preventing postoperative nausea and vomiting
245,CD003289,CD003289 v. 10.0 Tobacco cessation interventions for young people
246,CD003316,CD003316 v. 9.0 Physical fitness training for stroke patients
247,CD003317,CD003317 v. 5.2 Acupuncture for acute stroke
248,CD003328,CD003328 v. 8.0 Interventions for paracetamol (acetaminophen) overdose
249,CD003331,CD003331 v. 10.0 Exercise-based cardiac rehabilitation for adults with heart failure
250,CD003352,CD003352 v. 10.0 Dopamine agonists for the treatment of cocaine dependence
251,CD003357,CD003357 v. 8.0 In vitro fertilisation for unexplained subfertility
252,CD003362,CD003362 v. 8.0 Male circumcision for prevention of heterosexual acquisition of HIV in men
253,CD003363,CD003363 v. 5.2 Structural and community-level interventions for increasing condom use to prevent the transmission o
254,CD003366,CD003366 v. 11.0 Taxane-containing regimens for metastatic breast cancer
255,CD003372,CD003372 v. 8.3 Single agent versus combination chemotherapy for metastatic breast cancer
256,CD003374,CD003374 v. 10.0 Platinum-containing regimens for metastatic breast cancer
257,CD003380,CD003380 v. 13.0 Cognitive behavioural therapy (CBT) third-wave CBT and interpersonal therapy (IPT) based interventi
258,CD003388,CD003388 v. 15.0 Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults
259,CD003401,CD003401 v. 6.0 Combined spinal-epidural versus epidural analgesia in labour
260,CD003402,CD003402 v. 8.7 Omega-3 fatty acid addition during pregnancy
261,CD003406,CD003406 v. 7.17 Behavioural and cognitive-behavioural interventions for outwardly directed aggressive behaviour in p
262,CD003409,CD003409 v. 19.0 Methadone at tapered doses for the management of opioid withdrawal
263,CD003410,CD003410 v. 20.2 Heroin maintenance for chronic heroin-dependent individuals
264,CD003414,CD003414 v. 6.0 Cycle regimens for frozen-thawed embryo transfer
265,CD003434,CD003434 v. 9.0 Interventions for idiopathic intracranial hypertension
266,CD003437,CD003437 v. 7.6 Pharmacological non-invasive brain stimulation and psychological interventions and their combinati
267,CD003440,CD003440 v. 11.0 Workplace interventions for smoking cessation
268,CD003453,CD003453 v. 5.0 Orthodontic treatment for crowded teeth in children
269,CD003474,CD003474 v. 17.0 Bisphosphonates and other bone agents for breast cancer
270,CD003477,CD003477 v. 10.0 Music-based therapeutic interventions for people with dementia
271,CD003488,CD003488 v. 8.0 Corticosteroids for dengue infection
272,CD003505,CD003505 v. 7.0 Lifestyle interventions for the treatment of urinary incontinence in adults
273,CD003510,CD003510 v. 8.0 Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection
274,CD003511,CD003511 v. 13.0 Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology
275,CD003519,CD003519 v. 7.2 Early skin-to-skin contact for mothers and their healthy newborn infants
276,CD003543,CD003543 v. 12.0 Interventions to improve antibiotic prescribing practices for hospital inpatients
277,CD003575,CD003575 v. 15.0 Interventions for treating collagenous colitis
278,CD003582,CD003582 v. 10.0 Elective birth at 37 weeks gestation for women with an uncomplicated twin pregnancy
279,CD003586,CD003586 v. 5.78 Non-pharmacological interventions for spatial neglect or inattention following stroke and other non-
280,CD003587,CD003587 v. 11.0 Fast-track cardiac care for adult cardiac surgical patients
281,CD003594,CD003594 v. 14.0 Interventions for idiopathic steroid-resistant nephrotic syndrome in children
282,CD003633,CD003633 v. 6.0 Botulinum toxin type A therapy for cervical dystonia
283,CD003641,CD003641 v. 12.0 Surgery for weight loss in adults
284,CD003650,CD003650 v. 9.0 Micronutrient supplementation in adults with HIV infection
285,CD003664,CD003664 v. 8.0 Infant formulas containing hydrolysed protein for prevention of allergic disease
286,CD003680,CD003680 v. 15.0 Group-based parent training programmes for improving emotional and behavioural adjustment in young c
287,CD003689,CD003689 v. 6.0 Pharmacological psychological and non-invasive brain stimulation interventions for preventing depre
288,CD003698,CD003698 v. 7.0 Community pharmacy personnel interventions for smoking cessation
289,CD003709,CD003709 v. 7.0 Vasopressors for hypotensive shock
290,CD003719,CD003719 v. 10.0 Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in I
291,CD003721,CD003721 v. 9.0 Cancer genetic risk assessment for individuals at risk of familial breast cancer
292,CD003737,CD003737 v. 8.38 Interventions for intermittent exotropia
293,CD003748,CD003748 v. 8.14 Cilostazol for intermittent claudication
294,CD003751,CD003751 v. 10.2 Communication skills training for healthcare professionals working with people who have cancer
295,CD003753,CD003753 v. 9.3 Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis
296,CD003756,CD003756 v. 6.2 Intermittent preventive treatment for malaria in children living in areas with seasonal transmission
297,CD003793,CD003793 v. 9.0 Pulmonary rehabilitation for chronic obstructive pulmonary disease
298,CD003794,CD003794 v. 15.0 Combined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obst
299,CD003804,CD003804 v. 8.0 Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and d
300,CD003809,CD003809 v. 6.0 Fluorides for preventing early tooth decay (demineralised lesions) during fixed brace treatment
301,CD003811,CD003811 v. 6.163 Antibiotics to prevent complications following tooth extractions
302,CD003824,CD003824 v. 8.0 Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension
303,CD003842,CD003842 v. 7.0 Single double or multiple-injection techniques for non-ultrasound guided axillary brachial plexus b
304,CD003843,CD003843 v. 12.0 Bispectral index for improving intraoperative awareness and early postoperative recovery in adults
305,CD003860,CD003860 v. 10.0 Hypofractionated radiation therapy for early breast cancer
306,CD003861,CD003861 v. 13.209 Water for wound cleansing
307,CD003864,CD003864 v. 6.0 Interventions for improving oral health in people after stroke
308,CD003868,CD003868 v. 20.0 Oral morphine for cancer pain
309,CD003869,CD003869 v. 13.0 Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases
310,CD003870,CD003870 v. 16.27 Oxycodone for cancer-related pain
311,CD003871,CD003871 v. 10.0 Interventions to reduce Staphylococcus aureus in the management of eczema
312,CD003877,CD003877 v. 7.2 Sedation of children undergoing dental treatment
313,CD003893,CD003893 v. 8.0 Methyldopa for primary hypertension
314,CD003898,CD003898 v. 9.0 Inhaled magnesium sulfate in the treatment of acute asthma
315,CD003907,CD003907 v. 7.0 Strength training and aerobic exercise training for muscle disease
316,CD003909,CD003909 v. 14.4 Individual psychological therapy in the outpatient treatment of adults with anorexia nervosa
317,CD003919,CD003919 v. 3.135 Laser trabeculoplasty for open-angle glaucoma and ocular hypertension
318,CD003935,CD003935 v. 13.18 Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal h
319,CD003942,CD003942 v. 6.0 Professional structural and organisational interventions in primary care for reducing medication er
320,CD003944,CD003944 v. 6.0 Antidepressants for treating depression in dementia
321,CD003965,CD003965 v. 14.0 Immunosuppressive agents for treating IgA nephropathy
322,CD003968,CD003968 v. 20.0 Psychological therapies for the management of chronic and recurrent pain in children and adolescents
323,CD003976,CD003976 v. 6.0 Pharmacological interventions for pain relief during orthodontic treatment
324,CD003999,CD003999 v. 9.0 Relapse prevention interventions for smoking cessation
325,CD004003,CD004003 v. 7.3 Environmental sanitary interventions for preventing active trachoma
326,CD004008,CD004008 v. 7.0 Interventions for trachoma trichiasis
327,CD004011,CD004011 v. 5.562 Strategies for the removal of short-term indwelling urethral catheters in adults
328,CD004015,CD004015 v. 6.3 Lay health workers in primary and community health care for maternal and child health and the manage
329,CD004019,CD004019 v. 5.0 Osteotomy for treating knee osteoarthritis
330,CD004020,CD004020 v. 7.0 Braces and orthoses for treating osteoarthritis of the knee
331,CD004022,CD004022 v. 10.0 Effects of low sodium diet versus high sodium diet on blood pressure renin aldosterone catecholam
332,CD004025,CD004025 v. 8.0 Music therapy for people with schizophrenia and schizophrenia-like disorders
333,CD004034,CD004034 v. 8.180 Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the pr
334,CD004046,CD004046 v. 8.0 Acupuncture for depression
335,CD004048,CD004048 v. 12.0 Lithium for acute mania
336,CD004052,CD004052 v. 10.9 Valproate for acute mania
337,CD004055,CD004055 v. 5.0 Interventions for hand eczema
338,CD004063,CD004063 v. 8.0 Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer
339,CD004064,CD004064 v. 11.4 Chemotherapy for advanced gastric cancer
340,CD004069,CD004069 v. 9.0 Vitamin E supplementation in pregnancy
341,CD004072,CD004072 v. 9.0 Vitamin C supplementation in pregnancy
342,CD004073,CD004073 v. 7.0 Vitamin supplementation for preventing miscarriage
343,CD004075,CD004075 v. 13.0 Fetal pulse oximetry for fetal assessment in labour
344,CD004098,CD004098 v. 5.0 Levothyroxine or minimally invasive therapies for benign thyroid nodules
345,CD004107,CD004107 v. 4.0 Options for self-management education for adults with asthma
346,CD004122,CD004122 v. 8.301 Preoperative hair removal to reduce surgical site infection
347,CD004126,CD004126 v. 10.0 Alpha-2 adrenergic agonists for the prevention of cardiac complications among adults undergoing surg
348,CD004127,CD004127 v. 9.0 Noninvasive positive-pressure ventilation as a weaning strategy for intubated adults with respirator
349,CD004134,CD004134 v. 6.0 Interventions for improving patients' trust in doctors and groups of doctors
350,CD004136,CD004136 v. 13.0 Antihypertensive agents for preventing diabetic kidney disease
351,CD004143,CD004143 v. 7.2 Long-term hormone therapy for perimenopausal and postmenopausal women
352,CD004147,CD004147 v. 10.0 Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alon
353,CD004148,CD004148 v. 12.0 Effectiveness of brief alcohol interventions in primary care populations
354,CD004149,CD004149 v. 6.0 Constraint-induced movement therapy in children with unilateral cerebral palsy
355,CD004157,CD004157 v. 4.0 Treatment for cramps in amyotrophic lateral sclerosismotor neuron disease
356,CD004158,CD004158 v. 6.0 Rehabilitation following carpal tunnel release
357,CD004185,CD004185 v. 10.0 Fluoxetine versus other types of pharmacotherapy for depression
358,CD004192,CD004192 v. 9.9 Dietary interventions for multiple sclerosis-related outcomes
359,CD004197,CD004197 v. 12.11 Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
360,CD004198,CD004198 v. 9.0 Treatments for priapism in boys and men with sickle cell disease
361,CD004210,CD004210 v. 8.0 Interventions to prevent hypothermia at birth in preterm andor low birth weight infants
362,CD004253,CD004253 v. 11.0 Psychological interventions for women with metastatic breast cancer
363,CD004260,CD004260 v. 10.0 Continuous passive motion following total knee arthroplasty in people with arthritis
364,CD004265,CD004265 v. 8.51 Hand-washing promotion for preventing diarrhoea
365,CD004267,CD004267 v. 10.0 Antibiotics for ventilator-associated pneumonia
366,CD004282,CD004282 v. 8.0 Non-invasive interventions for improving well-being and quality of life in patients with lung cancer
367,CD004287,CD004287 v. 9.2 Tissue adhesives for closure of surgical incisions
368,CD004289,CD004289 v. 10.0 HMG CoA reductase inhibitors (statins) for dialysis patients
369,CD004294,CD004294 v. 6.3 Physical rehabilitation for older people in long-term care
370,CD004305,CD004305 v. 9.4 Healthcare financing systems for increasing the use of tobacco dependence treatment
371,CD004307,CD004307 v. 12.0 Incentives for smoking cessation
372,CD004317,CD004317 v. 10.0 Strategies to improve adherence and continuation of shorter-term hormonal methods of contraception
373,CD004345,CD004345 v. 6.29 Surgical techniques for the removal of mandibular wisdom teeth
374,CD004349,CD004349 v. 6.75 Blood pressure targets in adults with hypertension
375,CD004371,CD004371 v. 11.0 Interventions to improve adherence to lipid-lowering medication
376,CD004376,CD004376 v. 6.0 Exercise for osteoarthritis of the knee
377,CD004381,CD004381 v. 8.14 Music therapy for autistic people
378,CD004398,CD004398 v. 12.0 Printed educational materials effects on professional practice and healthcare outcomes
379,CD004414,CD004414 v. 5.0 Interventions for preventing occupational irritant hand dermatitis
380,CD004415,CD004415 v. 6.0 Interventions for actinic keratoses
381,CD004421,CD004421 v. 10.0 Taxanes for adjuvant treatment of early breast cancer
382,CD004433,CD004433 v. 7.0 Constraint-induced movement therapy for upper extremities in people with stroke
383,CD004434,CD004434 v. 9.0 Endothelin receptor antagonists for pulmonary arterial hypertension
384,CD004454,CD004454 v. 10.1 Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
385,CD004455,CD004455 v. 9.0 Antibiotic prophylaxis for operative vaginal delivery
386,CD004462,CD004462 v. 7.2 Interventions for treating urinary incontinence after stroke in adults
387,CD004476,CD004476 v. 5.0 Perioperative beta-blockers for preventing surgery-related mortality and morbidity
388,CD004477,CD004477 v. 10.0 Pharmacological agents for adults with acute respiratory distress syndrome
389,CD004492,CD004492 v. 9.0 Stage-based interventions for smoking cessation
390,CD004493,CD004493 v. 9.179 Family-based programmes for preventing smoking by children and adolescents
391,CD004523,CD004523 v. 10.154 Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal wom
392,CD004529,CD004529 v. 4.2 Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria
393,CD004536,CD004536 v. 7.0 Nutritional interventions for reducing morbidity and mortality in people with HIV
394,CD004538,CD004538 v. 6.2 Impact of public release of performance data on the behaviour of healthcare consumers and providers
395,CD004542,CD004542 v. 10.0 Psychosocial interventions for preventing and treating depression in dialysis patients
396,CD004559,CD004559 v. 12.0 Chinese medicinal herbs for influenza
397,CD004598,CD004598 v. 13.0 Local anaesthetic sympathetic blockade for complex regional pain syndrome
398,CD004615,CD004615 v. 5.2 Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria
399,CD004619,CD004619 v. 5.8 Coblation versus other surgical techniques for tonsillectomy
400,CD004622,CD004622 v. 8.6 Full-mouth treatment modalities (within 24 hours) for periodontitis in adults
401,CD004625,CD004625 v. 7.0 Routine scale and polish for periodontal health in adults
402,CD004634,CD004634 v. 9.5 Follicular flushing during oocyte retrieval in assisted reproductive techniques
403,CD004659,CD004659 v. 6.0 Antiplatelet agents for preventing pre-eclampsia and its complications
404,CD004661,CD004661 v. 7.0 Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus
405,CD004677,CD004677 v. 5.37 Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
406,CD004680,CD004680 v. 12.8 Catheter type placement and insertion techniques for preventing catheter-related infections in chro
407,CD004687,CD004687 v. 9.1 Short-term psychodynamic psychotherapies for common mental disorders
408,CD004690,CD004690 v. 9.0 Cognitive behavioural therapy for anxiety disorders in children and adolescents
409,CD004692,CD004692 v. 9.13 Omega-3 fatty acids for depression in adults
410,CD004705,CD004705 v. 9.0 Biomedical risk assessment as an aid for smoking cessation
411,CD004714,CD004714 v. 7.32 Treatment of periodontitis for glycaemic control in people with diabetes mellitus
412,CD004715,CD004715 v. 6.0 Pharmacological interventions for pain in patients with temporomandibular disorders
413,CD004736,CD004736 v. 8.0 Daily oral iron supplementation during pregnancy
414,CD004744,CD004744 v. 6.0 Rivastigmine for vascular cognitive impairment
415,CD004749,CD004749 v. 8.0 Interventions to increase the use of electronic health information by healthcare practitioners to im
416,CD004764,CD004764 v. 6.0 Patching for corneal abrasion
417,CD004767,CD004767 v. 11.0 Interventions for cutaneous molluscum contagiosum
418,CD004770,CD004770 v. 13.0 Drug therapy for delirium in terminally ill adults
419,CD004772,CD004772 v. 6.0 Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age
420,CD004773,CD004773 v. 8.0 Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people
421,CD004780,CD004780 v. 13.0 Family therapy approaches for anorexia nervosa
422,CD004794,CD004794 v. 5.0 Interventions to improve water quality for preventing diarrhoea
423,CD004795,CD004795 v. 6.0 Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)
424,CD004816,CD004816 v. 17.1 Statins for the primary prevention of cardiovascular disease
425,CD004834,CD004834 v. 7.0 Interventions for American cutaneous and mucocutaneous leishmaniasis
426,CD004851,CD004851 v. 11.38 Newer generation antidepressants for depressive disorders in children and adolescents
427,CD004863,CD004863 v. 11.0 Early erythropoiesis-stimulating agents in preterm or low birth weight infants
428,CD004873,CD004873 v. 14.50 Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old
429,CD004898,CD004898 v. 5.0 Monoamine oxidase B inhibitors for early Parkinson's disease
430,CD004905,CD004905 v. 14.0 Multiple-micronutrient supplementation for women during pregnancy
431,CD004908,CD004908 v. 7.0 Relief of pain due to uterine crampinginvolution after birth
432,CD004909,CD004909 v. 8.0 Fetal movement counting for assessment of fetal wellbeing
433,CD004910,CD004910 v. 5.0 Shared care across the interface between primary and specialty care in management of long term condi
434,CD004916,CD004916 v. 7.0 Interventions to slow progression of myopia in children
435,CD004945,CD004945 v. 10.0 Induction of labour at or beyond 37 weeks' gestation
436,CD004947,CD004947 v. 11.0 Prenatal administration of progesterone for preventing preterm birth in women considered to be at ri
437,CD004961,CD004961 v. 6.0 Intramedullary nails for extracapsular hip fractures in adults
438,CD004982,CD004982 v. 10.0 Treatment for superficial thrombophlebitis of the leg
439,CD005001,CD005001 v. 9.0 Exercise for women receiving adjuvant therapy for breast cancer
440,CD005004,CD005004 v. 9.0 Green tea (Camellia sinensis) for the prevention of cancer
441,CD005005,CD005005 v. 11.8 Hyperbaric oxygen therapy for late radiation tissue injury
442,CD005023,CD005023 v. 7.3 Vision screening for correctable visual acuity deficits in school-age children and adolescents
443,CD005027,CD005027 v. 8.0 Interventions for morphea
444,CD005043,CD005043 v. 7.0 Advocacy interventions to reduce or eliminate violence and promote the physical and psychosocial wel
445,CD005048,CD005048 v. 8.19 Interventions for dysphagia in oesophageal cancer
446,CD005051,CD005051 v. 4.5 Whole grain cereals for the primary or secondary prevention of cardiovascular disease
447,CD005061,CD005061 v. 4.0 Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated 
448,CD005067,CD005067 v. 9.0 Interventions for Old World cutaneous leishmaniasis
449,CD005068,CD005068 v. 7.0 Interventions for pityriasis rosea
450,CD005074,CD005074 v. 5.0 Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease
451,CD005083,CD005083 v. 11.0 Honey as a topical treatment for wounds
452,CD005085,CD005085 v. 4.0 Oximes for acute organophosphate pesticide poisoning
453,CD005103,CD005103 v. 4.0 Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabet
454,CD005105,CD005105 v. 3.59 Low glycaemic index or low glycaemic load diets for people with overweight or obesity
455,CD005134,CD005134 v. 7.0 Pentasaccharides for the prevention of venous thromboembolism
456,CD005139,CD005139 v. 7.0 Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
457,CD005143,CD005143 v. 6.0 Hyperbaric versus isobaric bupivacaine for spinal anaesthesia for caesarean section
458,CD005146,CD005146 v. 9.0 Haloperidol plus promethazine for psychosis-induced aggression
459,CD005158,CD005158 v. 6.0 Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events
460,CD005175,CD005175 v. 4.0 The medical use of cannabis for reducing morbidity and mortality in patients with HIVAIDS
461,CD005179,CD005179 v. 10.0 Psychological interventions for needle-related procedural pain and distress in children and adolesce
462,CD005186,CD005186 v. 7.2 Interventions to improve hand hygiene compliance in patient care
463,CD005215,CD005215 v. 7.0 Interventions for preventing unintended pregnancies among adolescents
464,CD005225,CD005225 v. 6.2 Creatine for amyotrophic lateral sclerosismotor neuron disease
465,CD005231,CD005231 v. 7.0 Interventions to reduce harm from continued tobacco use
466,CD005252,CD005252 v. 7.13 Avoidance of bottles during the establishment of breastfeeds in preterm infants
467,CD005258,CD005258 v. 5.19 Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of ve
468,CD005261,CD005261 v. 7.0 Endovascular treatment for ruptured abdominal aortic aneurysm
469,CD005263,CD005263 v. 6.0 Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermitten
470,CD005266,CD005266 v. 4.0 Screening for type 2 diabetes mellitus
471,CD005296,CD005296 v. 4.14 Single versus multiple visits for endodontic treatment of permanent teeth
472,CD005305,CD005305 v. 6.0 Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease
473,CD005315,CD005315 v. 4.0 Sensory environment on health-related outcomes of hospital patients
474,CD005328,CD005328 v. 6.2 Intra-articular corticosteroid for knee osteoarthritis
475,CD005330,CD005330 v. 6.0 Media-delivered cognitive behavioural therapy and behavioural therapy (self-help) for anxiety disord
476,CD005336,CD005336 v. 7.0 Psychosocial interventions for cannabis use disorder
477,CD005356,CD005356 v. 7.3 Agents for ovarian stimulation for intrauterine insemination (IUI) in ovulatory women with infertili
478,CD005370,CD005370 v. 10.0 Antithrombin III for critically ill patients
479,CD005379,CD005379 v. 7.0 Omega 3 fatty acid for the prevention of cognitive decline and dementia
480,CD005397,CD005397 v. 6.0 Vestibular rehabilitation for unilateral peripheral vestibular dysfunction
481,CD005411,CD005411 v. 3.2 Systemic interventions for recurrent aphthous stomatitis (mouth ulcers)
482,CD005427,CD005427 v. 6.0 Combined chiropractic interventions for low-back pain
483,CD005444,CD005444 v. 6.4 Pre-operative biliary drainage for obstructive jaundice
484,CD005449,CD005449 v. 3.0 Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in typ
485,CD005457,CD005457 v. 7.0 Carbetocin for preventing postpartum haemorrhage
486,CD005460,CD005460 v. 6.0 Traditional birth attendant training for improving health behaviours and pregnancy outcomes
487,CD005465,CD005465 v. 12.0 Interventions for preventing falls in older people in care facilities and hospitals
488,CD005468,CD005468 v. 3.0 TNF-alpha inhibitors for ankylosing spondylitis
489,CD005470,CD005470 v. 6.1 Tailored interventions to address determinants of practice
490,CD005481,CD005481 v. 7.0 Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS
491,CD005491,CD005491 v. 10.0 Corticosteroids for treating nerve damage in leprosy
492,CD005496,CD005496 v. 8.19 Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants
493,CD005508,CD005508 v. 4.0 Beta blockers for peripheral arterial disease
494,CD005512,CD005512 v. 4.3 Preformed crowns for decayed primary molar teeth
495,CD005528,CD005528 v. 5.11 Non-clinical interventions for reducing unnecessary caesarean section
496,CD005535,CD005535 v. 3.0 Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticost
497,CD005547,CD005547 v. 7.38 Effect of mass deworming with antihelminthics for soil-transmitted helminths during pregnancy
498,CD005552,CD005552 v. 6.2 Metformin versus the combined oral contraceptive pill for hirsutism acne and menstrual pattern in 
499,CD005555,CD005555 v. 3.152 Lens extraction for chronic angle-closure glaucoma
500,CD005562,CD005562 v. 5.29 Cognitive stimulation to improve cognitive functioning in people with dementia
501,CD005563,CD005563 v. 5.0 Interventions for preventing delirium in hospitalised non-ICU patients
502,CD005566,CD005566 v. 4.0 Prophylactic corticosteroids for cardiopulmonary bypass in adults
503,CD005573,CD005573 v. 6.0 Probiotics for induction of remission in ulcerative colitis
504,CD005594,CD005594 v. 6.0 Antipsychotics for treatment of delirium in hospitalised non-ICU patients
505,CD005595,CD005595 v. 3.0 Rehabilitation for ankle fractures in adults
506,CD005599,CD005599 v. 12.0 Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-rel
507,CD005614,CD005614 v. 6.0 Chondroitin for osteoarthritis
508,CD005619,CD005619 v. 4.6 Subacromial decompression surgery for rotator cuff disease
509,CD005620,CD005620 v. 4.27 Direct composite resin fillings versus amalgam fillings for permanent posterior teeth
510,CD005627,CD005627 v. 7.3 Diet or exercise or both for weight reduction in women after childbirth
511,CD005632,CD005632 v. 4.0 Steroid avoidance or withdrawal for kidney transplant recipients
512,CD005634,CD005634 v. 7.180 Specialist breast care nurses for support of women with breast cancer
513,CD005647,CD005647 v. 4.0 Treatment for HIV-associated cryptococcal meningitis
514,CD005652,CD005652 v. 7.0 Psychological therapies for people with borderline personality disorder
515,CD005654,CD005654 v. 6.0 Pelvic floor muscle training versus no treatment or inactive control treatments for urinary incont
516,CD005656,CD005656 v. 5.0 Intravitreal steroids for macular edema in diabetes
517,CD005937,CD005937 v. 4.0 Treatments for suppression of lactation
518,CD005944,CD005944 v. 6.0 Vitamin A supplementation for postpartum women
519,CD005949,CD005949 v. 4.0 Higher versus lower amino acid intake in parenteral nutrition for newborn infants
520,CD005950,CD005950 v. 9.0 Mental practice for treating upper extremity deficits in individuals with hemiparesis after stroke
521,CD005951,CD005951 v. 5.0 Haemostatic therapies for acute spontaneous intracerebral haemorrhage
522,CD005955,CD005955 v. 4.13 Exercise for acutely hospitalised older medical patients
523,CD005967,CD005967 v. 9.3 Artesunate versus quinine for treating severe malaria
524,CD005974,CD005974 v. 10.15 Homeopathic medicinal products for preventing and treating acute respiratory tract infections in chi
525,CD005978,CD005978 v. 11.0 Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months
526,CD005979,CD005979 v. 7.0 Pharmaceutical policies effects of reference pricing other pricing and purchasing policies
527,CD005982,CD005982 v. 5.0 Low molecular weight heparin for prevention of central venous catheter-related thrombosis in childre
528,CD005987,CD005987 v. 6.0 Scalpel versus electrosurgery for major abdominal incisions
529,CD005992,CD005992 v. 5.21 Legislative smoking bans for reducing harms from secondhand smoke exposure smoking prevalence and t
530,CD005998,CD005998 v. 6.79 Preoperative ripening of the cervix before operative hysteroscopy
531,CD006033,CD006033 v. 6.2 Steroidal contraceptives effect on bone fractures in women
532,CD006034,CD006034 v. 5.97 Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine-devi
533,CD006037,CD006037 v. 6.0 Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared
534,CD006073,CD006073 v. 5.0 Repetitive task training for improving functional ability after stroke
535,CD006077,CD006077 v. 5.0 Allopurinol for chronic gout
536,CD006086,CD006086 v. 5.2 Nutritional supplements for people being treated for active tuberculosis
537,CD006094,CD006094 v. 3.0 Interventions for improving the appropriate use of imaging in people with musculoskeletal conditions
538,CD006102,CD006102 v. 3.0 Smoking cessation interventions for smokers with current or past depression
539,CD006103,CD006103 v. 13.20 Nicotine receptor partial agonists for smoking cessation
540,CD006106,CD006106 v. 5.0 Pain relief in hysterosalpingography
541,CD006109,CD006109 v. 8.0 Oral contraceptive pill progestogen or oestrogen pretreatment for ovarian stimulation protocols for
542,CD006127,CD006127 v. 7.9 Blood pressure control for diabetic retinopathy
543,CD006132,CD006132 v. 5.2 Interventions for improving adherence to ocular hypotensive therapy
544,CD006135,CD006135 v. 4.0 Probiotics for treating eczema
545,CD006137,CD006137 v. 6.0 H1-antihistamines for chronic spontaneous urticaria
546,CD006145,CD006145 v. 8.0 Exercise for the management of cancer-related fatigue in adults
547,CD006146,CD006146 v. 9.0 Opioids for neuropathic pain
548,CD006170,CD006170 v. 6.2 Methods of milk expression for lactating women
549,CD006185,CD006185 v. 8.0 Electromechanical-assisted training for walking after stroke
550,CD006190,CD006190 v. 5.131 Colchicine for acute gout
551,CD006196,CD006196 v. 3.6 Intermittent drug techniques for schizophrenia
552,CD006205,CD006205 v. 7.13 Interventions for the treatment of oral cavity and oropharyngeal cancers surgical treatment
553,CD006207,CD006207 v. 11.26 Physical interventions to interrupt or reduce the spread of respiratory viruses
554,CD006208,CD006208 v. 5.0 Interventions for reducing medication errors in children in hospital
555,CD006211,CD006211 v. 4.19 Comprehensive geriatric assessment for older adults admitted to hospital
556,CD006213,CD006213 v. 9.0 Healing by primary versus secondary intention after surgical treatment for pilonidal sinus
557,CD006219,CD006219 v. 7.2 Interventions for preventing weight gain after smoking cessation
558,CD006237,CD006237 v. 8.6 Interventions to improve return to work in depressed people
559,CD006239,CD006239 v. 3.0 Pharmacological interventions for preventing post-traumatic stress disorder (PTSD)
560,CD006250,CD006250 v. 5.0 Bisphosphonates for advanced prostate cancer
561,CD006258,CD006258 v. 7.0 Haemodiafiltration haemofiltration and haemodialysis for end-stage kidney disease
562,CD006275,CD006275 v. 13.264 Non-pharmacological management of infant and young child procedural pain
563,CD006282,CD006282 v. 5.0 Drug treatment for spinal muscular atrophy types II and III
564,CD006318,CD006318 v. 8.0 Maintenance agonist treatments for opiate-dependent pregnant women
565,CD006349,CD006349 v. 7.0 Percutaneous vertebroplasty for osteoporotic vertebral compression fracture
566,CD006359,CD006359 v. 6.0 Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived 
567,CD006375,CD006375 v. 6.0 Mid-urethral sling operations for stress urinary incontinence in women
568,CD006380,CD006380 v. 9.0 Pharmacologic interventions for treating phantom limb pain
569,CD006383,CD006383 v. 3.2 Insulin detemir versus insulin glargine for type 2 diabetes mellitus
570,CD006387,CD006387 v. 3.0 Interventions for the treatment of oral cavity and oropharyngeal cancer radiotherapy
571,CD006389,CD006389 v. 3.0 Interventions to facilitate return to work in adults with adjustment disorders
572,CD006417,CD006417 v. 4.0 School-based interventions for preventing HIV sexually transmitted infections and pregnancy in ado
573,CD006418,CD006418 v. 4.0 Isoniazid for preventing tuberculosis in HIV-infected children
574,CD006419,CD006419 v. 5.0 Antihelminthics in helminth-endemic areas effects on HIV disease progression
575,CD006420,CD006420 v. 5.2 Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in hae
576,CD006423,CD006423 v. 5.0 Glucagon-like peptide analogues for type 2 diabetes mellitus
577,CD006424,CD006424 v. 3.0 Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes me
578,CD006425,CD006425 v. 6.0 Antenatal breastfeeding education for increasing breastfeeding duration
579,CD006429,CD006429 v. 5.0 Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify 
580,CD006430,CD006430 v. 3.565 Occupational therapy for cognitive impairment in stroke patients
581,CD006440,CD006440 v. 4.170 Remotely delivered information training and support for informal caregivers of people with dementia
582,CD006459,CD006459 v. 6.0 Ultrasound guidance for upper and lower limb blocks
583,CD006462,CD006462 v. 5.0 Early additional food and fluids for healthy breastfed full-term infants
584,CD006474,CD006474 v. 4.0 Prebiotics in infants for prevention of allergy
585,CD006487,CD006487 v. 4.0 Injectable local anaesthetic agents for dental anaesthesia
586,CD006489,CD006489 v. 6.0 Exercise programs for people with dementia
587,CD006491,CD006491 v. 7.0 Mefloquine for preventing malaria during travel to endemic areas
588,CD006525,CD006525 v. 5.0 Collaborative care for depression and anxiety problems
589,CD006534,CD006534 v. 4.0 Citalopram versus other anti-depressive agents for depression
590,CD006536,CD006536 v. 6.0 Stem cell treatment for acute myocardial infarction
591,CD006543,CD006543 v. 3.6 Low vision rehabilitation for better quality of life in visually impaired adults
592,CD006545,CD006545 v. 6.2 Interventions for infantile haemangiomas of the skin
593,CD006560,CD006560 v. 8.0 Interventions for improving outcomes in patients with multimorbidity in primary care and community s
594,CD006583,CD006583 v. 8.0 Laparoscopic entry techniques
595,CD006611,CD006611 v. 6.0 Mobile phone text messaging and app-based interventions for smoking cessation
596,CD006612,CD006612 v. 6.2 Homocysteine-lowering interventions for preventing cardiovascular events
597,CD006616,CD006616 v. 4.0 N-acetylcysteine for sepsis and systemic inflammatory response in adults
598,CD006641,CD006641 v. 4.0 Rooming-in for new mother and infant versus separate care for increasing the duration of breastfeedi
599,CD006650,CD006650 v. 28.7 Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer
600,CD006652,CD006652 v. 33.6 Parenteral anticoagulation in ambulatory patients with cancer
601,CD006657,CD006657 v. 4.0 Indoor residual spraying for preventing malaria
602,CD006674,CD006674 v. 5.0 Dietary advice interventions in pregnancy for preventing gestational diabetes mellitus
603,CD006683,CD006683 v. 4.8 Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after catara
604,CD006686,CD006686 v. 7.0 Bradykinin beta-2 receptor antagonists for acute traumatic brain injury
605,CD006706,CD006706 v. 2.0 Interventions for the prevention and treatment of herpes simplex virus in patients being treated for
606,CD006715,CD006715 v. 6.0 Epidural analgesia for adults undergoing cardiac surgery with or without cardiopulmonary bypass
607,CD006726,CD006726 v. 4.0 Psychological therapies for the treatment of post-traumatic stress disorder in children and adolesce
608,CD006727,CD006727 v. 5.0 Continuation and maintenance treatments for depression in older people
609,CD006732,CD006732 v. 5.32 Interventions for increasing the use of shared decision making by healthcare professionals
610,CD006748,CD006748 v. 6.0 Social norms information for alcohol misuse in university and college students
611,CD006749,CD006749 v. 5.0 Detoxification treatments for opiate dependent adolescents
612,CD006750,CD006750 v. 3.0 Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients
613,CD006754,CD006754 v. 8.0 Anticonvulsants for cocaine dependence
614,CD006763,CD006763 v. 4.12 Altered dietary salt intake for preventing diabetic kidney disease and its progression
615,CD006764,CD006764 v. 5.3 Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of 
616,CD006768,CD006768 v. 5.5 Interventions for convergence insufficiency a network meta-analysis
617,CD006771,CD006771 v. 5.0 Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
618,CD006772,CD006772 v. 4.0 Service organisation for the secondary prevention of ischaemic heart disease in primary care
619,CD006787,CD006787 v. 4.0 Music interventions for acquired brain injury
620,CD006788,CD006788 v. 11.0 Pharmacological treatments for fatigue associated with palliative care
621,CD006811,CD006811 v. 6.7 Interventions to reduce body temperature to 35 C to 37 C in adults and children with traumatic bra
622,CD006826,CD006826 v. 5.0 Combined corticosteroid and long-acting beta2-agonist in one inhaler versus inhaled corticosteroids 
623,CD006829,CD006829 v. 8.0 Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonis
624,CD006832,CD006832 v. 3.0 Interventions for preventing critical illness polyneuropathy and critical illness myopathy
625,CD006833,CD006833 v. 3.0 Reiki for depression and anxiety
626,CD006839,CD006839 v. 5.2 Treatment for ulnar neuropathy at the elbow
627,CD006842,CD006842 v. 9.0 Oscillating devices for airway clearance in people with cystic fibrosis
628,CD006847,CD006847 v. 3.0 Gefitinib for advanced non-small cell lung cancer
629,CD006850,CD006850 v. 5.0 Braces for idiopathic scoliosis in adolescents
630,CD006869,CD006869 v. 6.0 Multiple session early psychological interventions for the prevention of post-traumatic stress disor
631,CD006876,CD006876 v. 6.0 Electromechanical and robot-assisted arm training for improving activities of daily living arm func
632,CD006886,CD006886 v. 3.0 Psychosocial interventions for smoking cessation in patients with coronary heart disease
633,CD006887,CD006887 v. 5.3 Risk scoring for the primary prevention of cardiovascular disease
634,CD006896,CD006896 v. 4.0 Folic acid supplementation during pregnancy for maternal health and pregnancy outcomes
635,CD006901,CD006901 v. 4.0 Nitric oxide donors for cervical ripening and induction of labour
636,CD006911,CD006911 v. 9.11 Music interventions for improving psychological and physical outcomes in people with cancer
637,CD006918,CD006918 v. 4.3 Risperidone versus placebo for schizophrenia
638,CD006936,CD006936 v. 7.0 Motivational interviewing for smoking cessation
639,CD006955,CD006955 v. 4.0 Workplace interventions to prevent work disability in workers on sick leave
640,CD006968,CD006968 v. 11.2 Local interventions for the management of alveolar osteitis (dry socket)
641,CD006980,CD006980 v. 6.0 Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in
642,CD006981,CD006981 v. 3.111 Treatment for sialorrhea (excessive saliva) in people with motor neuron diseaseamyotrophic lateral 
643,CD007004,CD007004 v. 6.0 Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progr
644,CD007007,CD007007 v. 5.5 Screening women for intimate partner violence in healthcare settings
645,CD007019,CD007019 v. 5.2 Hospital nurse-staffing models and patient- and staff-related outcomes
646,CD007025,CD007025 v. 5.0 Motivational interviewing for the prevention of alcohol misuse in young adults
647,CD007030,CD007030 v. 4.0 Interventions for post-stroke fatigue
648,CD007039,CD007039 v. 4.4 Interventions for perceptual disorders following stroke
649,CD007049,CD007049 v. 3.0 Wound infiltration with local anaesthetic agents for laparoscopic cholecystectomy
650,CD007058,CD007058 v. 4.0 Ultrasound for fetal assessment in early pregnancy
651,CD007070,CD007070 v. 3.5 Acupuncture for treating fibromyalgia
652,CD007071,CD007071 v. 5.0 In-service training for health professionals to improve care of seriously ill newborns and children 
653,CD007078,CD007078 v. 10.1 Internet-based interventions for smoking cessation
654,CD007079,CD007079 v. 3.0 Calcium supplementation (other than for preventing or treating hypertension) for improving pregnancy
655,CD007084,CD007084 v. 9.4 Effects of sevoflurane versus other general anaesthesia on emergence agitation in children
656,CD007090,CD007090 v. 5.0 Comparison of different protein concentrations of human milk fortifier for promoting growth and neur
657,CD007094,CD007094 v. 6.0 Honey for acute cough in children
658,CD007095,CD007095 v. 6.0 Xylitol for preventing acute otitis media in children up to 12 years of age
659,CD007105,CD007105 v. 12.0 Local anaesthetics and regional anaesthesia versus conventional analgesia for preventing persistent 
660,CD007110,CD007110 v. 5.0 Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphom
661,CD007115,CD007115 v. 10.0 Duloxetine for treating painful neuropathy chronic pain or fibromyalgia
662,CD007125,CD007125 v. 3.226 Multidisciplinary rehabilitation for older people with hip fractures
663,CD007130,CD007130 v. 8.0 Home-based versus centre-based cardiac rehabilitation
664,CD007131,CD007131 v. 5.10 Interventions to promote patient utilisation of cardiac rehabilitation
665,CD007137,CD007137 v. 11.1 Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preter
666,CD007139,CD007139 v. 3.0 Alprazolam for depression
667,CD007145,CD007145 v. 4.0 Diet or exercise or both for preventing excessive weight gain in pregnancy
668,CD007146,CD007146 v. 12.0 Interventions for preventing falls in older people living in the community
669,CD007194,CD007194 v. 4.0 Debriefing interventions for the prevention of psychological trauma in women following childbirth
670,CD007198,CD007198 v. 3.3 Information and communication technology in patient education and support for people with schizophre
671,CD007210,CD007210 v. 3.0 Maintenance treatments for opiate-dependent adolescents
672,CD007222,CD007222 v. 10.0 Screening for gestational diabetes mellitus based on different risk profiles and settings for improv
673,CD007228,CD007228 v. 5.2 Structured telephone support or non-invasive telemonitoring for patients with heart failure
674,CD007239,CD007239 v. 5.0 Interventions for preventing mastitis after childbirth
675,CD007244,CD007244 v. 4.0 Black cohosh (Cimicifuga spp.) for menopausal symptoms
676,CD007249,CD007249 v. 5.0 Theory-based interventions for contraception
677,CD007253,CD007253 v. 5.13 Interventions for smoking cessation and reduction in individuals with schizophrenia
678,CD007260,CD007260 v. 4.0 Mechanical versus manual chest compressions for cardiac arrest
679,CD007272,CD007272 v. 5.5 Anaesthetic interventions for prevention of awareness during surgery
680,CD007275,CD007275 v. 2.0 Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours
681,CD007277,CD007277 v. 3.0 Abatacept for rheumatoid arthritis
682,CD007286,CD007286 v. 7.2 Antiepileptic drugs as prophylaxis for postcraniotomy seizures
683,CD007297,CD007297 v. 2.42 Shared decision-making interventions for people with mental health conditions
684,CD007298,CD007298 v. 7.0 Vitamin D supplementation for cystic fibrosis
685,CD007315,CD007315 v. 2.164 Perioperative glycaemic control for people with diabetes undergoing surgery
686,CD007324,CD007324 v. 6.0 Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusi
687,CD007337,CD007337 v. 3.91 Intraperitoneal local anaesthetic instillation versus no intraperitoneal local anaesthetic instillat
688,CD007354,CD007354 v. 9.0 Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in
689,CD007355,CD007355 v. 11.0 Single dose oral ketoprofen or dexketoprofen for acute postoperative pain in adults
690,CD007360,CD007360 v. 4.0 Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperp
691,CD007372,CD007372 v. 5.0 Home versus inpatient induction of labour for improving birth outcomes
692,CD007373,CD007373 v. 4.0 Interventions for pain with intrauterine device insertion
693,CD007380,CD007380 v. 5.0 Psychostimulant drugs for cocaine dependence
694,CD007393,CD007393 v. 10.0 Topical capsaicin (high concentration) for chronic neuropathic pain in adults
695,CD007399,CD007399 v. 10.0 The use of propofol for procedural sedation in emergency departments
696,CD007400,CD007400 v. 10.0 Topical NSAIDs for chronic musculoskeletal pain in adults
697,CD007402,CD007402 v. 14.0 Topical NSAIDs for acute musculoskeletal pain in adults
698,CD007407,CD007407 v. 13.0 Psychological therapies for the management of chronic pain (excluding headache) in adults
699,CD007410,CD007410 v. 4.5 Acupuncture for menopausal hot flushes
700,CD007411,CD007411 v. 20.2 Antioxidants for male subfertility
701,CD007412,CD007412 v. 6.0 Active versus expectant management for women in the third stage of labour
702,CD007419,CD007419 v. 9.14 Anti-vascular endothelial growth factor for diabetic macular oedema a network meta-analysis
703,CD007443,CD007443 v. 4.0 Probiotics for maintenance of remission in ulcerative colitis
704,CD007447,CD007447 v. 2.2 One-to-one oral hygiene advice provided in a dental setting for oral health
705,CD007451,CD007451 v. 4.0 Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension
706,CD007455,CD007455 v. 4.0 Stretch for the treatment and prevention of contractures
707,CD007458,CD007458 v. 3.0 Mobile phone messaging reminders for attendance at healthcare appointments
708,CD007464,CD007464 v. 3.2 Chemotherapy for brain metastases from small cell lung cancer
709,CD007469,CD007469 v. 3.6 Vitamin D supplementation for prevention of cancer in adults
710,CD007470,CD007470 v. 5.0 Vitamin D supplementation for prevention of mortality in adults
711,CD007471,CD007471 v. 6.1 Pelvic floor muscle training for preventing and treating urinary and faecal incontinence in antenata
712,CD007476,CD007476 v. 7.4 Deferasirox for managing iron overload in people with thalassaemia
713,CD007477,CD007477 v. 7.0 Deferasirox for managing transfusional iron overload in people with sickle cell disease
714,CD007478,CD007478 v. 2.1113 Interventions for cutaneous disease in systemic lupus erythematosus
715,CD007480,CD007480 v. 4.0 Vitamin A supplementation for the prevention of morbidity and mortality in infants one to six months
716,CD007483,CD007483 v. 3.0 Artemisinin-based combination therapy for treating uncomplicated malaria
717,CD007495,CD007495 v. 2.0 Professional interventions for general practitioners on the management of musculoskeletal conditions
718,CD007498,CD007498 v. 6.0 Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
719,CD007504,CD007504 v. 5.0 Interventions for preventing relapse and recurrence of a depressive disorder in children and adolesc
720,CD007506,CD007506 v. 8.0 Lifestyle changes in women with polycystic ovary syndrome
721,CD007513,CD007513 v. 5.0 Circuit class therapy for improving mobility after stroke
722,CD007522,CD007522 v. 2.0 Pharmacological therapies for management of opium withdrawal
723,CD007524,CD007524 v. 13.3 Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adul
724,CD007543,CD007543 v. 2.2 Enhanced glucose control for preventing and treating diabetic neuropathy
725,CD007546,CD007546 v. 3.27 Interventions for preventing and reducing the use of physical restraints for older people in all lon
726,CD007554,CD007554 v. 5.2 Biocompatible dialysis fluids for peritoneal dialysis
727,CD007566,CD007566 v. 5.0 Exercise interventions on health-related quality of life for cancer survivors
728,CD007568,CD007568 v. 2.0 Telephone interventions for symptom management in adults with cancer
729,CD007575,CD007575 v. 4.0 Interventions for nausea and vomiting in early pregnancy
730,CD007577,CD007577 v. 4.0 Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in criticall
731,CD007579,CD007579 v. 2.186 Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesar
732,CD007594,CD007594 v. 4.0 Hydroxyethyl starch (HES) versus other fluid therapies effects on kidney function
733,CD007598,CD007598 v. 4.0 Aromatherapy for treatment of postoperative nausea and vomiting
734,CD007614,CD007614 v. 3.0 Fresh frozen plasma for cardiovascular surgery
735,CD007622,CD007622 v. 5.0 Group versus conventional antenatal care for women
736,CD007628,CD007628 v. 5.2 Interventions for female pattern hair loss
737,CD007646,CD007646 v. 3.0 Community-based antibiotic delivery for possible serious bacterial infections in neonates in low- an
738,CD007647,CD007647 v. 2.0 Community-based maternal and newborn educational care packages for improving neonatal health and sur
739,CD007649,CD007649 v. 4.0 Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
740,CD007651,CD007651 v. 3.342 School-based physical activity programs for promoting physical activity and fitness in children and 
741,CD007662,CD007662 v. 2.20 Pharmacotherapy for trichotillomania
742,CD007667,CD007667 v. 4.0 Pharmacological interventions for antisocial personality disorder
743,CD007668,CD007668 v. 3.0 Psychological interventions for antisocial personality disorder
744,CD007672,CD007672 v. 2.3 Interventions to improve continuity of care in the follow-up of patients with cancer
745,CD007689,CD007689 v. 6.0 Acupuncture for polycystic ovarian syndrome
746,CD007694,CD007694 v. 6.0 Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmet
747,CD007701,CD007701 v. 3.0 Pharmacological and mechanical interventions for labour induction in outpatient settings
748,CD007718,CD007718 v. 3.0 Telehealthcare for chronic obstructive pulmonary disease
749,CD007724,CD007724 v. 6.0 Oral anti-diabetic agents for women with established diabetesimpaired glucose tolerance or previous
750,CD007726,CD007726 v. 4.4 Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological
751,CD007736,CD007736 v. 4.0 Educational supportive and behavioural interventions to improve usage of continuous positive airway
752,CD007738,CD007738 v. 4.0 Spectacle correction versus no spectacles for prevention of strabismus in hyperopic children
753,CD007745,CD007745 v. 3.0 Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection
754,CD007751,CD007751 v. 3.145 Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (st
755,CD007754,CD007754 v. 4.0 Community-based intervention packages for reducing maternal and neonatal morbidity and mortality and
756,CD007771,CD007771 v. 10.0 Vitamin D for the treatment of chronic painful conditions in adults
757,CD007776,CD007776 v. 4.0 Preconception care for diabetic women for improving maternal and infant health
758,CD007784,CD007784 v. 6.0 HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
759,CD007798,CD007798 v. 5.0 Clinically-indicated replacement versus routine replacement of peripheral venous catheters
760,CD007803,CD007803 v. 3.0 Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related
761,CD007807,CD007807 v. 6.0 Antioxidants for female subfertility
762,CD007813,CD007813 v. 4.0 Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults
763,CD007814,CD007814 v. 2.0 Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer
764,CD007818,CD007818 v. 5.0 Treatment for postpolio syndrome
765,CD007821,CD007821 v. 3.0 Heated insufflation with or without humidification for laparoscopic abdominal surgery
766,CD007825,CD007825 v. 8.0 Collaboration between local health and local government agencies for health improvement
767,CD007851,CD007851 v. 5.0 Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin 
768,CD007858,CD007858 v. 3.0 Blood pressure-lowering treatment for preventing recurrent stroke major vascular events and dement
769,CD007859,CD007859 v. 4.2 Initial arch wires used in orthodontic treatment with fixed appliances
770,CD007862,CD007862 v. 6.9 Active cycle of breathing technique for cystic fibrosis
771,CD007867,CD007867 v. 4.0 Prescribed hypocaloric nutrition support for critically-ill adults
772,CD007872,CD007872 v. 5.0 Tranexamic acid for preventing postpartum haemorrhage
773,CD007874,CD007874 v. 3.0 Lidocaine for reducing propofol-induced pain on induction of anaesthesia in adults
774,CD007876,CD007876 v. 4.0 Culture media for human pre-implantation embryos in assisted reproductive technology cycles
775,CD007888,CD007888 v. 3.0 Stem cell therapy for chronic ischaemic heart disease and congestive heart failure
776,CD007892,CD007892 v. 7.0 Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative in
777,CD007899,CD007899 v. 5.0 Paying for performance to improve the delivery of health interventions in low- and middle-income cou
778,CD007910,CD007910 v. 2.0 Interventions for lowering plasma homocysteine levels in kidney transplant recipients
779,CD007912,CD007912 v. 2.0 Exercise for osteoarthritis of the hip
780,CD007913,CD007913 v. 2.0 Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile n
781,CD007917,CD007917 v. 2.0 Light therapies for acne
782,CD007927,CD007927 v. 5.0 Epidermal growth factor receptor blockers for the treatment of ovarian cancer
783,CD007929,CD007929 v. 7.9 Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
784,CD007930,CD007930 v. 2.19 Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
785,CD007938,CD007938 v. 15.0 Gabapentin for chronic neuropathic pain in adults
786,CD007949,CD007949 v. 3.0 Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
787,CD007950,CD007950 v. 3.2 Effects and safety of periconceptional oral folate supplementation for preventing birth defects
788,CD007952,CD007952 v. 4.0 Incentives and enablers to improve adherence in tuberculosis
789,CD007961,CD007961 v. 2.81 Topical microbicides for preventing sexually transmitted infections
790,CD007964,CD007964 v. 2.7 Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia
791,CD007978,CD007978 v. 3.0 Email for clinical communication between patientscaregivers and healthcare professionals
792,CD007986,CD007986 v. 4.38 Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children a
793,CD008012,CD008012 v. 3.81 Psychological and pharmacological interventions for depression in patients with coronary artery dise
794,CD008016,CD008016 v. 4.7 Maintenance treatment with antipsychotic drugs for schizophrenia
795,CD008039,CD008039 v. 8.0 Ibuprofen with or without an antiemetic for acute migraine headaches in adults
796,CD008063,CD008063 v. 4.0 Motivational interviewing for substance abuse
797,CD008080,CD008080 v. 2.3 Intratympanic corticosteroids for sudden sensorineural hearing loss
798,CD008106,CD008106 v. 5.10 Surgical versus non-surgical interventions for treating patellar dislocation
799,CD008112,CD008112 v. 5.0 Spinal manipulative therapy for chronic low-back pain
800,CD008141,CD008141 v. 2.3 Second-generation antipsychotics for obsessive compulsive disorder
801,CD008144,CD008144 v. 4.0 Educational interventions for the management of cancer-related fatigue in adults
802,CD008145,CD008145 v. 3.0 Interventions for improving coverage of childhood immunisation in low- and middle-income countries
803,CD008152,CD008152 v. 6.0 Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission
804,CD008161,CD008161 v. 3.10 First-line diuretics versus other classes of antihypertensive drugs for hypertension
805,CD008165,CD008165 v. 4.2 Interventions to improve the appropriate use of polypharmacy for older people
806,CD008168,CD008168 v. 2.31 Intermittent phototherapy versus continuous phototherapy for neonatal jaundice
807,CD008170,CD008170 v. 3.0 First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive dr
808,CD008189,CD008189 v. 3.155 Preconception lifestyle advice for people with infertility
809,CD008201,CD008201 v. 3.0 Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous t
810,CD008203,CD008203 v. 3.0 Statins for primary prevention of venous thromboembolism
811,CD008207,CD008207 v. 3.0 Continuous passive motion for preventing venous thromboembolism after total knee arthroplasty
812,CD008208,CD008208 v. 8.0 Non-invasive brain stimulation techniques for chronic pain
813,CD008213,CD008213 v. 3.1 Surgical interventions for primary congenital glaucoma
814,CD008215,CD008215 v. 5.2 Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility
815,CD008218,CD008218 v. 4.7 Anti-angiogenic therapy for high-grade glioma
816,CD008226,CD008226 v. 5.0 Atorvastatin for lowering lipids
817,CD008239,CD008239 v. 8.199 Perioperative enhanced recovery programmes for women with gynaecological cancers
818,CD008242,CD008242 v. 10.0 Amitriptyline for neuropathic pain in adults
819,CD008250,CD008250 v. 2.0 Breathing exercises for chronic obstructive pulmonary disease
820,CD008251,CD008251 v. 3.0 Topical phenytoin for treating pressure ulcers
821,CD008276,CD008276 v. 2.1 Pharmacotherapy for hypertension in adults aged 18 to 59 years
822,CD008286,CD008286 v. 4.0 Combined pharmacotherapy and behavioural interventions for smoking cessation
823,CD008294,CD008294 v. 7.0 Pine bark (Pinus spp.) extract for treating chronic disorders
824,CD008307,CD008307 v. 5.1 Pharmacotherapy for the prevention of chronic pain after surgery in adults
825,CD008320,CD008320 v. 9.8 Pharmacological interventions for pruritus in adult palliative care patients
826,CD008324,CD008324 v. 4.0 Psychological therapies versus antidepressant medication alone and in combination for depression in
827,CD008326,CD008326 v. 5.0 Total disc replacement for chronic back pain in the presence of disc degeneration
828,CD008328,CD008328 v. 2.8 Airway clearance techniques for chronic obstructive pulmonary disease
829,CD008333,CD008333 v. 3.0 Anti-cytokine targeted therapies for ANCA-associated vasculitis
830,CD008334,CD008334 v. 2.0 Biologic interventions for fatigue in rheumatoid arthritis
831,CD008341,CD008341 v. 2.0 Golimumab for rheumatoid arthritis
832,CD008345,CD008345 v. 3.0 Case management approaches to home support for people with dementia
833,CD008349,CD008349 v. 5.0 Virtual reality for stroke rehabilitation
834,CD008366,CD008366 v. 5.0 Community wide interventions for increasing physical activity
835,CD008367,CD008367 v. 6.92 Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia
836,CD008381,CD008381 v. 2.2 Psychological and pharmacological interventions for depression in patients with diabetes mellitus an
837,CD008388,CD008388 v. 5.0 Interventions for visual field defects in people with stroke
838,CD008398,CD008398 v. 3.0 Oral versus intravenous fluoropyrimidines for colorectal cancer
839,CD008409,CD008409 v. 5.4 Progesterone for acute traumatic brain injury
840,CD008422,CD008422 v. 3.5 Vitamin D for the management of multiple sclerosis
841,CD008435,CD008435 v. 3.0 Skin-to-skin care for procedural pain in neonates
842,CD008449,CD008449 v. 3.3 Mirror therapy for improving motor function after stroke
843,CD008452,CD008452 v. 4.0 Hormonal contraceptives for contraception in overweight or obese women
844,CD008465,CD008465 v. 5.0 Exercise interventions on health-related quality of life for people with cancer during active treatm
845,CD008469,CD008469 v. 4.0 Home-based educational interventions for children with asthma
846,CD008472,CD008472 v. 2.15 Remote ischaemic preconditioning versus no remote ischaemic preconditioning for vascular and endovas
847,CD008474,CD008474 v. 6.0 Ozone therapy for treating foot ulcers in people with diabetes
848,CD008481,CD008481 v. 3.0 Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections
849,CD008492,CD008492 v. 4.0 Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria
850,CD008500,CD008500 v. 5.3 Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
851,CD008509,CD008509 v. 3.0 Alpha-blockers as medical expulsive therapy for ureteral stones
852,CD008521,CD008521 v. 7.7 Vaccines for preventing rotavirus diarrhoea vaccines in use
853,CD008524,CD008524 v. 7.18 Vitamin A supplementation for preventing morbidity and mortality in children from six months to five
854,CD008544,CD008544 v. 2.0 Anticonvulsants for alcohol dependence
855,CD008552,CD008552 v. 47.5 Interventions for increasing fruit and vegetable consumption in children aged five years and under
856,CD008558,CD008558 v. 2.0 Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in pe
857,CD008559,CD008559 v. 3.4 Atypical antipsychotics for disruptive behaviour disorders in children and youths
858,CD008563,CD008563 v. 2.0 Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection
859,CD008565,CD008565 v. 3.170 Statins for women with polycystic ovary syndrome not actively trying to conceive
860,CD008567,CD008567 v. 6.0 General physical health advice for people with serious mental illness
861,CD008570,CD008570 v. 5.2 Ergonomic interventions for preventing work-related musculoskeletal disorders of the upper limb and 
862,CD008572,CD008572 v. 2.2 Radiofrequency denervation for chronic low back pain
863,CD008600,CD008600 v. 3.0 Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrilla
864,CD008603,CD008603 v. 3.0 Oral vaccines for preventing cholera
865,CD008605,CD008605 v. 3.64 Dopamine agonists for preventing ovarian hyperstimulation syndrome
866,CD008618,CD008618 v. 3.2 Exercise for improving outcomes after osteoporotic vertebral fracture
867,CD008630,CD008630 v. 5.0 Pharmacological treatment other than corticosteroids intravenous immunoglobulin and plasma exchange
868,CD008646,CD008646 v. 2.7 Psychological preparation and postoperative outcomes for adults undergoing surgery under general ana
869,CD008649,CD008649 v. 4.0 Inhaled mannitol for cystic fibrosis
870,CD008653,CD008653 v. 2.0 Febuxostat for treating chronic gout
871,CD008661,CD008661 v. 3.0 Modafinil for people with schizophrenia or related disorders
872,CD008666,CD008666 v. 5.0 Vitamin A supplementation during pregnancy for maternal and newborn outcomes
873,CD008676,CD008676 v. 4.0 Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
874,CD008687,CD008687 v. 2.0 Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care un
875,CD008709,CD008709 v. 3.0 Single-incision sling operations for urinary incontinence in women
876,CD008712,CD008712 v. 10.0 Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatm
877,CD008716,CD008716 v. 5.5 Probiotics for people with hepatic encephalopathy
878,CD008720,CD008720 v. 2.5 Human chorionic gonadotrophin priming for fertility treatment with in vitro maturation
879,CD008726,CD008726 v. 2.243 Different classes of antibiotics given to women routinely for preventing infection at caesarean sect
880,CD008728,CD008728 v. 4.0 Interventions for preventing falls in people after stroke
881,CD008729,CD008729 v. 2.17 Psychological interventions for women with non-metastatic breast cancer
882,CD008732,CD008732 v. 2.6 Macular grid laser photocoagulation for branch retinal vein occlusion
883,CD008735,CD008735 v. 4.0 Glucocorticosteroids for infants with biliary atresia following Kasai portoenterostomy
884,CD008736,CD008736 v. 2.2 Vector and reservoir control for preventing leishmaniasis
885,CD008742,CD008742 v. 2.1 Conservative interventions for treating work-related complaints of the arm neck or shoulder in adul
886,CD008754,CD008754 v. 5.0 Memory rehabilitation for people with multiple sclerosis
887,CD008772,CD008772 v. 2.0 Probiotics for preventing urinary tract infections in adults and children
888,CD008776,CD008776 v. 2.0 Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus
889,CD008802,CD008802 v. 3.0 Oral health education (advice and training) for people with serious mental illness
890,CD008823,CD008823 v. 1.1364 Walking for hypertension
891,CD008824,CD008824 v. 2.0 Vitamin D supplementation for preventing infections in children under five years of age
892,CD008831,CD008831 v. 6.0 Probiotics for the preventionor treatment of chemotherapy- or radiotherapy-related diarrhoea in peo
893,CD008834,CD008834 v. 4.256 Antiplatelet agents for chronic kidney disease
894,CD008873,CD008873 v. 5.0 Vitamin D supplementation for women during pregnancy
895,CD008875,CD008875 v. 3.0 Post-pyloric versus gastric tube feeding for preventing pneumonia and improving nutritional outcomes
896,CD008895,CD008895 v. 6.0 Patient education in the management of coronary heart disease
897,CD008907,CD008907 v. 4.68 Eslicarbazepine acetate add-on therapy for drug-resistant focal epilepsy
898,CD008937,CD008937 v. 2.4 Psychological therapies for pathological and problem gambling
899,CD008940,CD008940 v. 4.0 Pharmacotherapies for cannabis dependence
900,CD008943,CD008943 v. 5.0 Combination pharmacotherapy for the treatment of neuropathic pain in adults
901,CD008958,CD008958 v. 4.0 The WHO Health Promoting School framework for improving the health and well-being of students and th
902,CD008959,CD008959 v. 7.0 Home fortification of foods with multiple micronutrient powders for health and nutrition in children
903,CD008962,CD008962 v. 2.0 Shock wave therapy for rotator cuff disease with or without calcification
904,CD008963,CD008963 v. 2.0 Self-management education programmes for osteoarthritis
905,CD008966,CD008966 v. 2.0 B-type natriuretic peptide-guided treatment for heart failure
906,CD008982,CD008982 v. 2.0 Postpartum misoprostol for preventing maternal mortality and morbidity
907,CD008986,CD008986 v. 4.46 Medication review in hospitalised patients to reduce morbidity and mortality
908,CD009000,CD009000 v. 4.0 Ready-to-use therapeutic food (RUTF) for home-based nutritional rehabilitation of severe acute malnu
909,CD009002,CD009002 v. 3.0 Omega-3 fatty acids for the treatment of dementia
910,CD009009,CD009009 v. 4.6 General health checks in adults for reducing morbidity and mortality from disease
911,CD009012,CD009012 v. 3.0 Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis
912,CD009066,CD009066 v. 2.0 Probiotics for preventing ventilator-associated pneumonia
913,CD009068,CD009068 v. 4.0 Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dyst
914,CD009075,CD009075 v. 3.0 Aerobic physical exercise for adult patients with haematological malignancies
915,CD009076,CD009076 v. 3.0 Interventions for treating femoral shaft fractures in children and adolescents
916,CD009081,CD009081 v. 1.343 Withdrawal or continuation of cholinesterase inhibitors or memantine or both in people with dementi
917,CD009103,CD009103 v. 4.10 Interventions for improving modifiable risk factor control in the secondary prevention of stroke
918,CD009115,CD009115 v. 3.6 Phonics training for English-speaking poor readers
919,CD009122,CD009122 v. 3.0 Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus
920,CD009124,CD009124 v. 4.0 Pushingbearing down methods for the second stage of labour
921,CD009125,CD009125 v. 2.38 Psychological treatments for depression and anxiety in dementia and mild cognitive impairment
922,CD009138,CD009138 v. 2.0 Amitriptyline versus placebo for major depressive disorder
923,CD009147,CD009147 v. 3.0 Image-guided glucocorticoid injection versus injection without image guidance for shoulder pain
924,CD009149,CD009149 v. 4.219 Primary-level worker interventions for the care of people living with mental disorders and distress 
925,CD009153,CD009153 v. 5.0 Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples
926,CD009154,CD009154 v. 10.0 Luteal phase support for assisted reproduction cycles
927,CD009163,CD009163 v. 3.0 Antibiotics for otitis media with effusion in children
928,CD009164,CD009164 v. 3.0 Interventions to increase adherence to medications for tobacco dependence
929,CD009172,CD009172 v. 3.0 Alternative lipid emulsions versus pure soy oil based lipid emulsions for parenterally fed preterm i
930,CD009176,CD009176 v. 5.0 Daily sedation interruption versus no daily sedation interruption for critically ill adult patients 
931,CD009178,CD009178 v. 4.0 Pharmacotherapies for sleep disturbances in dementia
932,CD009186,CD009186 v. 2.0 Strategies to increase the ownership and use of insecticide-treated bednets to prevent malaria
933,CD009187,CD009187 v. 2.0 Interventions for recruiting smokers into cessation programmes
934,CD009195,CD009195 v. 2.0 Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemi
935,CD009209,CD009209 v. 4.0 Workplace pedometer interventions for increasing physical activity
936,CD009218,CD009218 v. 7.0 Intermittent iron supplementation for reducing anaemia and its associated impairments in adolescent 
937,CD009231,CD009231 v. 5.0 Hospital at home home-based end-of-life care
938,CD009232,CD009232 v. 4.0 Acupuncture or acupressure for pain management during labour
939,CD009233,CD009233 v. 3.0 Environmental and behavioural interventions for reducing physical activity limitation and preventing
940,CD009238,CD009238 v. 3.0 Helminth therapy (worms) for allergic rhinitis
941,CD009241,CD009241 v. 3.0 Oxytocin augmentation of labour in women with epidural analgesia for reducing operative deliveries
942,CD009261,CD009261 v. 11.7 Negative pressure wound therapy for surgical wounds healing by primary closure
943,CD009275,CD009275 v. 4.0 Different types of dietary advice for women with gestational diabetes mellitus
944,CD009286,CD009286 v. 5.9 Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery
945,CD009287,CD009287 v. 2.0 Media campaigns for the prevention of illicit drug use in young people
946,CD009297,CD009297 v. 5.0 Darbepoetin for the anaemia of chronic kidney disease
947,CD009308,CD009308 v. 1.0 Universal family-based prevention programs for alcohol misuse in young people
948,CD009315,CD009315 v. 4.0 Nutritional labelling for healthier food or non-alcoholic drink purchasing and consumption
949,CD009326,CD009326 v. 4.54 Schedules for home visits in the early postpartum period
950,CD009332,CD009332 v. 5.0 Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of
951,CD009338,CD009338 v. 2.0 Telephone support for women during pregnancy and the first six weeks postpartum
952,CD009346,CD009346 v. 3.0 Pharmacological and non-pharmacological interventions for reducing rocuronium bromide induced pain o
953,CD009348,CD009348 v. 2.0 Injected corticosteroids for treating plantar heel pain in adults
954,CD009356,CD009356 v. 3.0 Hypnosis for pain management during labour and childbirth
955,CD009361,CD009361 v. 2.2 Colesevelam for type 2 diabetes mellitus
956,CD009362,CD009362 v. 4.0 Dressings and topical agents for preventing pressure ulcers
957,CD009363,CD009363 v. 4.2 Surgical versus conservative interventions for treating fractures of the middle third of the clavicl
958,CD009384,CD009384 v. 3.8 Zinc supplementation for preventing mortality morbidity and growth failure in children aged 6 mont
959,CD009386,CD009386 v. 2.0 Internet-based interventions for the secondary prevention of coronary heart disease
960,CD009401,CD009401 v. 3.3 Interventions to improve the use of systematic reviews in decision-making by health system managers
961,CD009409,CD009409 v. 1.89 Effect of periodontal treatments on blood pressure
962,CD009414,CD009414 v. 3.0 Interventions for preventing or reducing domestic violence against pregnant women
963,CD009419,CD009419 v. 4.0 Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease
964,CD009431,CD009431 v. 3.3 Prokinetics for functional dyspepsia
965,CD009434,CD009434 v. 1.253 Laser therapy for dentinal hypersensitivity
966,CD009435,CD009435 v. 3.0 Oral isotretinoin for acne
967,CD009437,CD009437 v. 2.462 Integrated disease management interventions for patients with chronic obstructive pulmonary disease
968,CD009445,CD009445 v. 2.0 Interventions to promote informed consent for patients undergoing surgical and other invasive health
969,CD009457,CD009457 v. 2.0 Isotonic versus hypotonic solutions for maintenance intravenous fluid administration in children
970,CD009458,CD009458 v. 3.0 Oral and intrauterine progestogens for atypical endometrial hyperplasia
971,CD009471,CD009471 v. 3.0 Inhaled corticosteroids in children with persistent asthma effects on growth
972,CD009484,CD009484 v. 2.2 Vapocoolants (cold spray) for pain treatment during intravenous cannulation
973,CD009501,CD009501 v. 2.0 Psychological interventions for co-occurring depression and substance use disorders
974,CD009504,CD009504 v. 3.0 Bupropion for attention deficit hyperactivity disorder (ADHD) in adults
975,CD009510,CD009510 v. 3.2 Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusio
976,CD009517,CD009517 v. 3.119 Endometrial injury in women undergoing in vitro fertilisation (IVF)
977,CD009532,CD009532 v. 2.0 Oral or parenteral iron supplementation to reduce deferral iron deficiency andor anaemia in blood 
978,CD009537,CD009537 v. 3.0 Interventions for preventing delirium in older people in institutional long-term care
979,CD009567,CD009567 v. 5.0 Interventions for treating acute high altitude illness
980,CD009568,CD009568 v. 2.0 Paediatric formulations of artemisinin-based combination therapies for treating uncomplicated malari
981,CD009576,CD009576 v. 2.98 Antibiotic therapy versus no antibiotic therapy for children aged 2 to 59 months with WHO-defined no
982,CD009577,CD009577 v. 5.2 Long-acting FSH versus daily FSH for women undergoing assisted reproduction
983,CD009580,CD009580 v. 3.0 Fibrates for secondary prevention of cardiovascular disease and stroke
984,CD009585,CD009585 v. 2.5 Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma
985,CD009586,CD009586 v. 4.1 Systematic screening for the detection of atrial fibrillation
986,CD009595,CD009595 v. 5.0 Autogenic drainage for airway clearance in cystic fibrosis
987,CD009608,CD009608 v. 1.337 Cognitive behavioural therapy (group) for schizophrenia
988,CD009611,CD009611 v. 3.0 Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults
989,CD009612,CD009612 v. 2.0 Nasal decongestants in monotherapy for the common cold
990,CD009613,CD009613 v. 5.0 Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes
991,CD009621,CD009621 v. 5.9 Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery
992,CD009629,CD009629 v. 4.0 Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms se
993,CD009638,CD009638 v. 3.0 Modes of exercise training for intermittent claudication
994,CD009642,CD009642 v. 4.0 Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adult
995,CD009645,CD009645 v. 4.0 Transcranial direct current stimulation (tDCS) for improving activities of daily living and physica
996,CD009650,CD009650 v. 5.7 Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people wit
997,CD009651,CD009651 v. 2.189 Interventions for treating fractures of the patella in adults
998,CD009652,CD009652 v. 2.0 Psychosocial interventions for benzodiazepine harmful use abuse or dependence
999,CD009660,CD009660 v. 7.1 Psychological interventions for parents of children and adolescents with chronic illness
1000,CD009670,CD009670 v. 5.2 Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation
1001,CD009677,CD009677 v. 2.0 Mobile clinics for women's and children's health
1002,CD009678,CD009678 v. 2.0 Nutritional interventions for survivors of childhood cancer
1003,CD009699,CD009699 v. 2.0 Red blood cell transfusion for people undergoing hip fracture surgery
1004,CD009720,CD009720 v. 4.9 Oral stimulation for promoting oral feeding in preterm infants
1005,CD009727,CD009727 v. 2.0 Goal setting and strategies to enhance goal pursuit for adults with acquired disability participatin
1006,CD009728,CD009728 v. 4.0 Physical activity diet and other behavioural interventions for improving cognition and school achie
1007,CD009729,CD009729 v. 2.0 Over the counter (OTC) artificial tear drops for dry eye syndrome
1008,CD009744,CD009744 v. 2.0 Niacin for primary and secondary prevention of cardiovascular events
1009,CD009745,CD009745 v. 2.2 Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion
1010,CD009747,CD009747 v. 3.0 Daily iron supplementation for improving anaemia iron status and health in menstruating women
1011,CD009749,CD009749 v. 2.0 Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction
1012,CD009752,CD009752 v. 2.0 Red cell transfusion management for patients undergoing cardiac surgery for congenital heart disease
1013,CD009753,CD009753 v. 3.0 Fibrates for primary prevention of cardiovascular disease events
1014,CD009758,CD009758 v. 2.0 Interventions for the prevention of recurrent erysipelas and cellulitis
1015,CD009760,CD009760 v. 4.0 Transcranial direct current stimulation (tDCS) for improving aphasia in adults with aphasia after st
1016,CD009764,CD009764 v. 4.0 Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
1017,CD009774,CD009774 v. 3.0 Parent-mediated early intervention for young children with autism spectrum disorders (ASD)
1018,CD009780,CD009780 v. 3.3 Implementation of treatment guidelines for specialist mental health care
1019,CD009782,CD009782 v. 2.0 Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery
1020,CD009783,CD009783 v. 6.0 Interventions for preventing intensive care unit delirium in adults
1021,CD009789,CD009789 v. 2.0 Antioxidants for preventing and reducing muscle soreness after exercise
1022,CD009790,CD009790 v. 2.0 Exercise therapy for chronic low back pain
1023,CD009796,CD009796 v. 3.0 Cognitive behavioural therapies for fibromyalgia
1024,CD009799,CD009799 v. 2.3 Laser-assisted subepithelial keratectomy (LASEK) versus photorefractive keratectomy (PRK) for correc
1025,CD009812,CD009812 v. 2.10 Personally tailored activities for improving psychosocial outcomes for people with dementia in long-
1026,CD009814,CD009814 v. 2.0 Trocar types in laparoscopy
1027,CD009825,CD009825 v. 4.0 Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
1028,CD009834,CD009834 v. 4.0 Antibiotics for persistent cough or wheeze following acute bronchiolitis in children
1029,CD009840,CD009840 v. 2.2 Supportive interventions for enhancing dietary intake in malnourished or nutritionally at-risk adult
1030,CD009841,CD009841 v. 3.0 Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
1031,CD009848,CD009848 v. 3.0 Exercise for reducing fear of falling in older people living in the community
1032,CD009861,CD009861 v. 4.3 Melatonin for preoperative and postoperative anxiety in adults
1033,CD009865,CD009865 v. 3.0 Celecoxib for osteoarthritis
1034,CD009868,CD009868 v. 3.0 Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
1035,CD009873,CD009873 v. 4.0 Massage with or without aromatherapy for symptom relief in people with cancer
1036,CD009882,CD009882 v. 3.0 Teriflunomide for multiple sclerosis
1037,CD009883,CD009883 v. 2.0 Thrombopoietin mimetics for patients with myelodysplastic syndromes
1038,CD009885,CD009885 v. 4.40 Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
1039,CD009889,CD009889 v. 3.0 Nurse-led titration of angiotensin converting enzyme inhibitors beta-adrenergic blocking agents an
1040,CD009891,CD009891 v. 2.0 Warming of intravenous and irrigation fluids for preventing inadvertent perioperative hypothermia
1041,CD009899,CD009899 v. 1.0 Exercise and mobilisation interventions for carpal tunnel syndrome
1042,CD009902,CD009902 v. 2.0 Fortification of rice with vitamins and minerals for addressing micronutrient malnutrition
1043,CD009904,CD009904 v. 2.0 Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease
1044,CD009905,CD009905 v. 2.1 Community coalition-driven interventions to reduce health disparities among racial and ethnic minori
1045,CD009912,CD009912 v. 5.0 Psychosocial interventions for informal caregivers of people living with cancer
1046,CD009921,CD009921 v. 2.2 Automated telephone communication systems for preventive healthcare and management of long-term cond
1047,CD009926,CD009926 v. 2.8 Subsidising artemisinin-based combination therapy in the private retail sector
1048,CD009927,CD009927 v. 4.1 Individual- family- and school-level interventions targeting multiple risk behaviours in young peo
1049,CD009934,CD009934 v. 2.0 Green and black tea for the primary prevention of cardiovascular disease
1050,CD009941,CD009941 v. 3.0 Femoral nerve blocks for acute postoperative pain after knee replacement surgery
1051,CD009953,CD009953 v. 2.0 Tai Chi for chronic obstructive pulmonary disease (COPD)
1052,CD009956,CD009956 v. 2.0 Exercise therapy for fatigue in multiple sclerosis
1053,CD009961,CD009961 v. 2.0 Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders 
1054,CD009984,CD009984 v. 5.0 Psychological interventions for acute pain after open heart surgery
1055,CD009985,CD009985 v. 3.11 Reducing medication errors for adults in hospital settings
1056,CD009992,CD009992 v. 2.0 Topical antifungal treatments for tinea cruris and tinea corporis
1057,CD009993,CD009993 v. 2.0 Interleukin-1 inhibitors for acute gout
1058,CD010001,CD010001 v. 3.0 Vasodilators for women undergoing fertility treatment
1059,CD010003,CD010003 v. 1.49 Splinting for carpal tunnel syndrome
1060,CD010013,CD010013 v. 2.0 Smartphone and tablet self management apps for asthma
1061,CD010015,CD010015 v. 5.0 Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration
1062,CD010031,CD010031 v. 3.0 Oral antifungal medication for toenail onychomycosis
1063,CD010037,CD010037 v. 3.0 Calcium supplementation for prevention of primary hypertension
1064,CD010038,CD010038 v. 3.0 Face-to-face interventions for informing or educating parents about early childhood vaccination
1065,CD010041,CD010041 v. 3.0 Interventions for supporting pregnant women's decision-making about mode of birth after a caesarean
1066,CD010061,CD010061 v. 4.12 Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants
1067,CD010063,CD010063 v. 2.0 Chromium picolinate supplementation for overweight or obese adults
1068,CD010068,CD010068 v. 2.4 Fortification of staple foods with vitamin A for vitamin A deficiency
1069,CD010069,CD010069 v. 4.4 Interventions for tophi in gout
1070,CD010070,CD010070 v. 2.158 Altered dietary salt intake for people with chronic kidney disease
1071,CD010072,CD010072 v. 3.0 Yoga for the primary prevention of cardiovascular disease
1072,CD010078,CD010078 v. 3.0 Pharmacological interventions for promoting smoking cessation during pregnancy
1073,CD010085,CD010085 v. 2.0 Maternal prenatal andor postnatal n-3 long chain polyunsaturated fatty acids (LCPUFA) supplementati
1074,CD010089,CD010089 v. 3.0 Influenza vaccines for preventing acute otitis media in infants and children
1075,CD010106,CD010106 v. 3.0 Drugs for the treatment of nausea and vomiting in adults in the emergency department setting
1076,CD010112,CD010112 v. 2.2 Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy
1077,CD010115,CD010115 v. 4.0 Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
1078,CD010118,CD010118 v. 4.3 Preoperative physical therapy for elective cardiac surgery patients
1079,CD010120,CD010120 v. 4.8 Non-steroidal anti-inflammatory drugs for acute gout
1080,CD010123,CD010123 v. 2.0 Integrated management of childhood illness (IMCI) strategy for children under five
1081,CD010130,CD010130 v. 3.13 Biomarkers as point-of-care tests to guide prescription of antibiotics in people with acute respirat
1082,CD010137,CD010137 v. 2.0 Glucose targets for preventing diabetic kidney disease and its progression
1083,CD010140,CD010140 v. 2.0 Skin antisepsis for reducing central venous catheter-related infections
1084,CD010143,CD010143 v. 2.3 Surgery for Dupuytren's contracture of the fingers
1085,CD010152,CD010152 v. 8.0 Psychological therapies (Internet-delivered) for the management of chronic pain in adults
1086,CD010157,CD010157 v. 2.0 Behavioural interventions to promote workers' use of respiratory protective equipment
1087,CD010166,CD010166 v. 5.0 Population-level interventions in government jurisdictions for dietary sodium reduction
1088,CD010172,CD010172 v. 6.0 High-flow nasal cannulae for respiratory support in adult intensive care patients
1089,CD010176,CD010176 v. 3.38 Interventions for replacing missing teeth alveolar ridge preservation techniques for dental implant
1090,CD010177,CD010177 v. 2.0 Long-acting beta2-agonists for chronic obstructive pulmonary disease
1091,CD010192,CD010192 v. 7.3 Interventions for promoting habitual exercise in people living with and beyond cancer
1092,CD010198,CD010198 v. 3.0 Virtual reality training for improving the skills needed for performing surgery of the ear nose or 
1093,CD010203,CD010203 v. 2.0 High-intensity versus low-intensity physical activity or exercise in people with hip or knee osteoar
1094,CD010204,CD010204 v. 2.0 Psychological therapies for post-traumatic stress disorder and comorbid substance use disorder
1095,CD010205,CD010205 v. 3.0 Zinc supplementation for the promotion of growth and prevention of infections in infants less than s
1096,CD010215,CD010215 v. 2.0 Psychological interventions for people with hemophilia
1097,CD010216,CD010216 v. 26.27 Electronic cigarettes for smoking cessation
1098,CD010232,CD010232 v. 3.0 Interventions aimed at communities to inform andor educate about early childhood vaccination
1099,CD010239,CD010239 v. 5.0 Lower versus higher oxygen concentrations titrated to target oxygen saturations during resuscitation
1100,CD010242,CD010242 v. 2.0 Mycophenolate mofetil for relapsing-remitting multiple sclerosis
1101,CD010252,CD010252 v. 2.4 Antibody induction versus corticosteroid induction for liver transplant recipients
1102,CD010254,CD010254 v. 4.0 Rosuvastatin for lowering lipids
1103,CD010255,CD010255 v. 3.0 Telerehabilitation services for stroke
1104,CD010257,CD010257 v. 3.0 Antibiotics for exacerbations of chronic obstructive pulmonary disease
1105,CD010263,CD010263 v. 2.0 Non-pharmacological interventions for alleviating pain during orthodontic treatment
1106,CD010266,CD010266 v. 2.0 Antibiotic prophylaxis for preventing infectious complications in orthognathic surgery
1107,CD010274,CD010274 v. 3.0 Interventions for tobacco use cessation in people in treatment for or recovery from substance use di
1108,CD010287,CD010287 v. 6.18 Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary sy
1109,CD010292,CD010292 v. 5.0 Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia
1110,CD010315,CD010315 v. 7.4 Blood pressure targets for the treatment of people with hypertension and cardiovascular disease
1111,CD010321,CD010321 v. 2.0 Interventions for preventing abuse in the elderly
1112,CD010323,CD010323 v. 8.1 Interventions for the reduction of prescribed opioid use in chronic non-cancer pain
1113,CD010324,CD010324 v. 3.1 Enzyme replacement and substrate reduction therapy for Gaucher disease
1114,CD010334,CD010334 v. 3.0 Interventions for hirsutism (excluding laser and photoepilation therapy alone)
1115,CD010342,CD010342 v. 5.0 Interventions to improve hearing aid use in adult auditory rehabilitation
1116,CD010346,CD010346 v. 3.0 Yoga for asthma
1117,CD010356,CD010356 v. 2.1 Preoperative inspiratory muscle training for postoperative pulmonary complications in adults undergo
1118,CD010358,CD010358 v. 2.5 Perioperative dexmedetomidine for acute pain after abdominal surgery in adults
1119,CD010365,CD010365 v. 2.0 Continuous versus interrupted skin sutures for non-obstetric surgery
1120,CD010383,CD010383 v. 3.89 First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squam
1121,CD010389,CD010389 v. 2.0 Imiquimod for anogenital warts in non-immunocompromised adults
1122,CD010390,CD010390 v. 2.0 Qigong for the primary prevention of cardiovascular disease
1123,CD010395,CD010395 v. 2.0 Remote and web 2.0 interventions for promoting physical activity
1124,CD010398,CD010398 v. 1.2 The effect of pharmacist-provided non-dispensing services on patient outcomes health service utilis
1125,CD010410,CD010410 v. 4.0 Low dose naltrexone for induction of remission in Crohn's disease
1126,CD010411,CD010411 v. 4.0 Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease
1127,CD010443,CD010443 v. 4.0 Combined diet and exercise interventions for preventing gestational diabetes mellitus
1128,CD010455,CD010455 v. 5.0 Down-titration and discontinuation strategies of tumour necrosis factorblocking agents for rheumato
1129,CD010461,CD010461 v. 4.0 Advanced sperm selection techniques for assisted reproduction
1130,CD010468,CD010468 v. 3.0 Diaries for recovery from critical illness
1131,CD010469,CD010469 v. 2.15 Corticosteroid implants for chronic non-infectious uveitis
1132,CD010485,CD010485 v. 2.0 Interventions for treating genital Chlamydia trachomatis infection in pregnancy
1133,CD010494,CD010494 v. 2.186 Mobility training for increasing mobility and functioning in older people with frailty
1134,CD010496,CD010496 v. 2.0 Probiotics for vulvovaginal candidiasis in non-pregnant women
1135,CD010512,CD010512 v. 2.0 Endovascular revascularisation versus conservative management for intermittent claudication
1136,CD010515,CD010515 v. 2.6 Personally tailored activities for improving psychosocial outcomes for people with dementia in commu
1137,CD010516,CD010516 v. 2.4 Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after unco
1138,CD010523,CD010523 v. 3.0 Personalised care planning for adults with chronic or long-term health conditions
1139,CD010526,CD010526 v. 3.0 Dental cavity liners for Class I and Class II resin-based composite restorations
1140,CD010529,CD010529 v. 7.6 Interventions for the management of malignant pleural effusions a network meta-analysis
1141,CD010534,CD010534 v. 2.0 Parent-infant psychotherapy for improving parental and infant mental health
1142,CD010535,CD010535 v. 2.0 Oral health educational interventions for nursing home staff and residents
1143,CD010538,CD010538 v. 2.0 Topical herbal therapies for treating osteoarthritis
1144,CD010551,CD010551 v. 3.0 Pelvic floor muscle training added to another active treatment versus the same active treatment alon
1145,CD010554,CD010554 v. 2.5 Yoga versus standard care for schizophrenia
1146,CD010557,CD010557 v. 2.0 Pharmacological interventions for treatment-resistant depression in adults
1147,CD010558,CD010558 v. 3.0 Psychological therapies for treatment-resistant depression in adults
1148,CD010569,CD010569 v. 3.0 Enhanced rehabilitation and care models for adults with dementia following hip fracture surgery
1149,CD010585,CD010585 v. 6.0 Combination pharmacotherapy for the treatment of fibromyalgia in adults
1150,CD010590,CD010590 v. 2.39 Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease a network meta-
1151,CD010592,CD010592 v. 2.3 Intranasal corticosteroids for non-allergic rhinitis
1152,CD010596,CD010596 v. 3.0 Exercise versus no exercise for the occurrence severity and duration of acute respiratory infectio
1153,CD010599,CD010599 v. 2.0 Anthelmintic drugs for treating ascariasis
1154,CD010606,CD010606 v. 2.162 Interventions for treating fractures of the distal femur in adults
1155,CD010610,CD010610 v. 3.0 Topiramate for the prophylaxis of episodic migraine in adults
1156,CD010613,CD010613 v. 2.2 Intensity of continuous renal replacement therapy for acute kidney injury
1157,CD010640,CD010640 v. 2.11 Iron therapy in anaemic adults without chronic kidney disease
1158,CD010641,CD010641 v. 2.4 Person-directed non-pharmacological interventions for sleepiness at work and sleep disturbances cau
1159,CD010643,CD010643 v. 2.0 Hyaluronic acid and other conservative treatment options for osteoarthritis of the ankle
1160,CD010651,CD010651 v. 2.0 Surgical versus non-surgical management for pleural empyema
1161,CD010660,CD010660 v. 2.0 Interventions for managing asthma in pregnancy
1162,CD010662,CD010662 v. 2.0 Behavioral interventions for improving condom use for dual protection
1163,CD010666,CD010666 v. 1.6 Micronutrient supplementation for children with HIV infection
1164,CD010668,CD010668 v. 1.109 Belimumab for systemic lupus erythematosus
1165,CD010669,CD010669 v. 2.0 Tools developed and disseminated by guideline producers to promote the uptake of their guidelines
1166,CD010671,CD010671 v. 2.95 Yoga for chronic non-specific low back pain
1167,CD010675,CD010675 v. 2.0 Surgical interventions (microfracture drilling mosaicplasty and allograft transplantation) for tr
1168,CD010678,CD010678 v. 3.2 Artemether for severe malaria
1169,CD010681,CD010681 v. 7.0 Adjuvant chemotherapy for advanced endometrial cancer
1170,CD010683,CD010683 v. 3.5 Methods to decrease blood loss during liver resection a network meta-analysis
1171,CD010690,CD010690 v. 2.1 Interventions for chronic kidney disease-associated restless legs syndrome
1172,CD010693,CD010693 v. 6.5 Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other 
1173,CD010697,CD010697 v. 2.0 Fortification of staple foods with zinc for improving zinc status and other health outcomes in the g
1174,CD010703,CD010703 v. 2.0 Eszopiclone for insomnia
1175,CD010734,CD010734 v. 2.0 Iodine fortification of foods and condiments other than salt for preventing iodine deficiency diso
1176,CD010735,CD010735 v. 2.84 Laser-assisted cataract surgery versus standard ultrasound phacoemulsification cataract surgery
1177,CD010736,CD010736 v. 2.0 Oxandrolone for growth hormone-treated girls aged up to 18 years with Turner syndrome
1178,CD010737,CD010737 v. 2.0 Advance care planning for haemodialysis patients
1179,CD010742,CD010742 v. 2.2 System change interventions for smoking cessation
1180,CD010743,CD010743 v. 2.5 Xylitol-containing products for preventing dental caries in children and adults
1181,CD010744,CD010744 v. 4.0 Smoking cessation for people with chronic obstructive pulmonary disease
1182,CD010747,CD010747 v. 2.2 Autologous cells derived from different sources and administered using different regimens for 'no-op
1183,CD010753,CD010753 v. 2.0 Antidepressants for insomnia in adults
1184,CD010754,CD010754 v. 3.0 Early intervention (mobilization or active exercise) for critically ill adults in the intensive care
1185,CD010756,CD010756 v. 5.1 Corticosteroids for the management of cancer-related pain in adults
1186,CD010758,CD010758 v. 3.0 Vilanterol and fluticasone furoate for asthma
1187,CD010763,CD010763 v. 2.0 Patient-initiated appointment systems for adults with chronic conditions in secondary care
1188,CD010766,CD010766 v. 6.0 Chelation for autism spectrum disorder (ASD)
1189,CD010767,CD010767 v. 2.2 Intermittent preventive antimalarial treatment for children with anaemia
1190,CD010770,CD010770 v. 2.0 Selective progesterone receptor modulators (SPRMs) for uterine fibroids
1191,CD010777,CD010777 v. 2.0 Ischaemic preconditioning for the reduction of renal ischaemia reperfusion injury
1192,CD010784,CD010784 v. 3.2 Medical and surgical interventions for the treatment of urinary stones in children
1193,CD010789,CD010789 v. 2.0 Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after
1194,CD010791,CD010791 v. 2.0 Impact of medication reconciliation for improving transitions of care
1195,CD010801,CD010801 v. 3.16 Transfusion of red blood cells stored for shorter versus longer duration for all conditions
1196,CD010802,CD010802 v. 2.5 Yoga for improving health-related quality of life mental health and cancer-related symptoms in wome
1197,CD010806,CD010806 v. 2.0 Psychosocial group interventions to improve psychological well-being in adults living with HIV
1198,CD010816,CD010816 v. 2.2 Bortezomib for the treatment of multiple myeloma
1199,CD010840,CD010840 v. 2.0 Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults
1200,CD010842,CD010842 v. 2.0 Exercise interventions and patient beliefs for people with hip knee or hip and knee osteoarthritis
1201,CD010844,CD010844 v. 2.0 Long-acting inhaled therapy (beta-agonists anticholinergics and steroids) for COPD a network meta-
1202,CD010853,CD010853 v. 5.15 Physiotherapy for pain and disability in adults with complex regional pain syndrome (CRPS) types I a
1203,CD010856,CD010856 v. 4.0 Water fluoridation for the prevention of dental caries
1204,CD010862,CD010862 v. 3.2 Pharmacological interventions for drug-using offenders
1205,CD010866,CD010866 v. 2.0 Screening for genital chlamydia infection
1206,CD010872,CD010872 v. 1.29 Fibrin-based haemostatic agents for reducing blood loss in adult liver resection
1207,CD010880,CD010880 v. 3.0 Peer support for people with schizophrenia or other serious mental illness
1208,CD010887,CD010887 v. 4.10 Non-surgical adjunctive interventions for accelerating tooth movement in patients undergoing orthodo
1209,CD010893,CD010893 v. 15.0 Interventions for reducing inflammation in familial Mediterranean fever
1210,CD010901,CD010901 v. 3.4 Interventions for drug-using offenders with co-occurring mental health problems
1211,CD010905,CD010905 v. 3.0 Human resource management training of supervisors for improving health and well-being of employees
1212,CD010907,CD010907 v. 3.0 Interventions to facilitate shared decision making to address antibiotic use for acute respiratory i
1213,CD010910,CD010910 v. 4.0 Interventions for female drug-using offenders
1214,CD010912,CD010912 v. 5.0 Workplace interventions for reducing sitting at work
1215,CD010915,CD010915 v. 2.0 Behavioral interventions for improving dual-method contraceptive use
1216,CD010927,CD010927 v. 1.0 Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
1217,CD010931,CD010931 v. 2.0 Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility
1218,CD010947,CD010947 v. 2.3 Cerebral near-infrared spectroscopy (NIRS) for perioperative monitoring of brain oxygenation in chil
1219,CD010951,CD010951 v. 2.7 Autologous blood and platelet-rich plasma injection therapy for lateral elbow pain
1220,CD010954,CD010954 v. 2.5 Immunonutrition for patients undergoing surgery for head and neck cancer
1221,CD010956,CD010956 v. 5.19 Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for 
1222,CD010957,CD010957 v. 3.13 Oral direct thrombin inhibitors or oral factor Xa inhibitorsversus conventional anticoagulants for 
1223,CD010959,CD010959 v. 3.0 Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis s
1224,CD010960,CD010960 v. 2.0 Injection therapies for Achilles tendinopathy
1225,CD010965,CD010965 v. 2.0 Interventions for chronic non-hypovolaemic hypotonic hyponatraemia
1226,CD010966,CD010966 v. 3.220 Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFT
1227,CD010969,CD010969 v. 3.0 Harms of off-label erythropoiesis-stimulating agents for critically ill people
1228,CD010971,CD010971 v. 3.0 Psychosocial interventions for recurrent abdominal pain in childhood
1229,CD010972,CD010972 v. 2.0 Dietary interventions for recurrent abdominal pain in childhood
1230,CD010973,CD010973 v. 2.0 Pharmacological interventions for recurrent abdominal pain in childhood
1231,CD010980,CD010980 v. 2.0 Methods for blood loss estimation after vaginal birth
1232,CD010994,CD010994 v. 3.0 Health system and community level interventions for improving antenatal care coverage and health out
1233,CD011004,CD011004 v. 2.0 Psychological therapies for panic disorder with or without agoraphobia in adults a network meta-ana
1234,CD011006,CD011006 v. 4.6 Antidepressants for the treatment of depression in people with cancer
1235,CD011010,CD011010 v. 1.23 High flow nasal cannula for respiratory support in term infants
1236,CD011015,CD011015 v. 2.0 Treatment for superficial infusion thrombophlebitis of the upper extremity
1237,CD011016,CD011016 v. 2.0 Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease
1238,CD011019,CD011019 v. 4.10 Telerehabilitation for people with low vision
1239,CD011020,CD011020 v. 3.0 Technological aids for the rehabilitation of memory and executive functioning in children and adoles
1240,CD011024,CD011024 v. 2.0 Interventions for increasing acceptance of local anaesthetic in children and adolescents having dent
1241,CD011027,CD011027 v. 2.53 Oral dextrose gel for the treatment of hypoglycaemia in newborn infants
1242,CD011031,CD011031 v. 3.0 Laparoscopic surgery for endometriosis
1243,CD011032,CD011032 v. 2.0 Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adu
1244,CD011038,CD011038 v. 2.0 Topical antimicrobial agents for treating foot ulcers in people with diabetes
1245,CD011044,CD011044 v. 2.0 Chemotherapy and radiotherapy for advanced pancreatic cancer
1246,CD011045,CD011045 v. 7.0 Portion package or tableware size for changing selection and consumption of food alcohol and tobac
1247,CD011055,CD011055 v. 2.0 Interventions to improve disposal of child faeces for preventing diarrhoea and soil-transmitted helm
1248,CD011056,CD011056 v. 8.0 Impact of morphine fentanyl oxycodone or codeine on patient consciousness appetite and thirst whe
1249,CD011057,CD011057 v. 3.0 Risperidone versus other antipsychotics for people with severe mental illness and co-occurring subst
1250,CD011058,CD011058 v. 2.0 Caregiver-mediated exercises for improving outcomes after stroke
1251,CD011064,CD011064 v. 2.0 Calcium channel blockers for people with chronic kidney disease requiring dialysis
1252,CD011066,CD011066 v. 2.0 Dehydroepiandrosterone for women in the peri- or postmenopausal phase
1253,CD011069,CD011069 v. 2.1 Different methods and settings for glucose monitoring for gestational diabetes during pregnancy
1254,CD011090,CD011090 v. 2.0 Effects of opioid hypnotic and sedating medications on sleep-disordered breathing in adults with ob
1255,CD011094,CD011094 v. 6.0 Omega-6 fats for the primary and secondary prevention of cardiovascular disease
1256,CD011101,CD011101 v. 2.3 Interventions to reduce shoulder pain following gynaecological laparoscopic procedures
1257,CD011107,CD011107 v. 2.2 Alpha-2 adrenergic agonists for the prevention of shivering following general anaesthesia
1258,CD011108,CD011108 v. 2.66 Hydromorphone for cancer pain
1259,CD011109,CD011109 v. 2.4 Probing for congenital nasolacrimal duct obstruction
1260,CD011110,CD011110 v. 3.0 Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
1261,CD011117,CD011117 v. 8.8 Opioid agonist treatment for people who are dependent on pharmaceutical opioids
1262,CD011118,CD011118 v. 6.0 Psychological therapies (remotely delivered) for the management of chronic and recurrent pain in chi
1263,CD011120,CD011120 v. 2.0 Interventions for tobacco use cessation in people living with HIV and AIDS
1264,CD011123,CD011123 v. 4.0 Systemic treatments for metastatic cutaneous melanoma
1265,CD011129,CD011129 v. 2.0 Early palliative care for adults with advanced cancer
1266,CD011135,CD011135 v. 4.11 Unconditional cash transfers for reducing poverty and vulnerabilities effect on use of health servi
1267,CD011136,CD011136 v. 5.0 Videolaryngoscopy versus direct laryngoscopy for adults undergoing tracheal intubation
1268,CD011138,CD011138 v. 2.0 Parenteral fluid regimens for improving functional outcome in people with acute stroke
1269,CD011151,CD011151 v. 4.0 Intraoperative use of low volume ventilation to decrease postoperative mortality mechanical ventila
1270,CD011152,CD011152 v. 3.0 Home-based multidimensional survivorship programmes for breast cancer survivors
1271,CD011154,CD011154 v. 3.0 Topical benzoyl peroxide for acne
1272,CD011159,CD011159 v. 2.134 Mobile phone-based interventions for improving contraception use
1273,CD011188,CD011188 v. 3.7 Corticosteroids for the treatment of Kawasaki disease in children
1274,CD011207,CD011207 v. 3.0 Community pharmacy interventions for health promotion effects on professional practice and health o
1275,CD011216,CD011216 v. 3.0 Complementary and alternative therapies for post-caesarean pain
1276,CD011220,CD011220 v. 2.0 Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer
1277,CD011227,CD011227 v. 3.0 Non-medical prescribing versus medical prescribing for acute and chronic disease management in prima
1278,CD011230,CD011230 v. 2.3 Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
1279,CD011244,CD011244 v. 3.2 Tobacco packaging design for reducing tobacco use
1280,CD011246,CD011246 v. 3.2 Prevention of depression in adults with long-term physical conditions
1281,CD011248,CD011248 v. 4.0 Breastfeeding for procedural pain in infants beyond the neonatal period
1282,CD011261,CD011261 v. 2.2 Ergonomic interventions for preventing musculoskeletal disorders in dental care practitioners
1283,CD011265,CD011265 v. 2.0 Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy
1284,CD011272,CD011272 v. 3.165 Rapamycin and rapalogs for tuberous sclerosis complex
1285,CD011277,CD011277 v. 2.0 Alginate dressings for treating pressure ulcers
1286,CD011281,CD011281 v. 2.0 Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis
1287,CD011283,CD011283 v. 3.0 Processed electroencephalogram and evoked potential techniques for amelioration of postoperative del
1288,CD011285,CD011285 v. 4.11 Exercise-based rehabilitation programmes for pulmonary hypertension
1289,CD011287,CD011287 v. 2.0 Dietary interventions for adult cancer survivors
1290,CD011292,CD011292 v. 2.0 Physical activity for women with breast cancer after adjuvant therapy
1291,CD011296,CD011296 v. 2.0 Sliding scale insulin for non-critically ill hospitalised adults with diabetes mellitus
1292,CD011301,CD011301 v. 3.0 Botulinum toxin type A for facial wrinkles
1293,CD011305,CD011305 v. 2.0 Restrictive versus liberal red blood cell transfusion strategies for people with haematological mali
1294,CD011315,CD011315 v. 2.0 Cognitive-behavioural treatment for amphetamine-type stimulants (ATS)-use disorders
1295,CD011320,CD011320 v. 7.0 Time-lapse systems for embryo incubation and assessment in assisted reproduction
1296,CD011321,CD011321 v. 3.0 Exercise programmes for ankylosing spondylitis
1297,CD011325,CD011325 v. 3.0 Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment
1298,CD011345,CD011345 v. 2.0 Timed intercourse for couples trying to conceive
1299,CD011353,CD011353 v. 3.1 Omega-3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease
1300,CD011358,CD011358 v. 3.0 Magnesium for treating sickle cell disease
1301,CD011360,CD011360 v. 2.0 Written information for patients (or parents of child patients) to reduce the use of antibiotics for
1302,CD011365,CD011365 v. 2.0 Tonsillectomy versus tonsillotomy for obstructive sleep-disordered breathing in children
1303,CD011368,CD011368 v. 3.0 Topical azelaic acid salicylic acid nicotinamide sulphur zinc and fruit acid (alpha-hydroxy acid
1304,CD011378,CD011378 v. 2.0 Nutritional interventions for treating foot ulcers in people with diabetes
1305,CD011381,CD011381 v. 2.9 Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis a network meta-a
1306,CD011384,CD011384 v. 2.0 Pharmacological interventions for acute pancreatitis
1307,CD011385,CD011385 v. 3.0 Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand
1308,CD011387,CD011387 v. 2.4 Total intravenous anaesthesia versus inhalational anaesthesia for adults undergoing transabdominal r
1309,CD011389,CD011389 v. 3.0 Laparoscopic versus open gastrectomy for gastric cancer
1310,CD011393,CD011393 v. 2.0 Interventions for itch in people with advanced chronic kidney disease
1311,CD011395,CD011395 v. 1.89 PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer
1312,CD011396,CD011396 v. 2.10 Interventions for raising breast cancer awareness in women
1313,CD011400,CD011400 v. 3.0 Food fortification with multiple micronutrients impact on health outcomes in general population
1314,CD011403,CD011403 v. 2.3 Treatment for hepatitis C virus-associated mixed cryoglobulinaemia
1315,CD011423,CD011423 v. 3.0 Autologous platelet concentrates for treating periodontal infrabony defects
1316,CD011424,CD011424 v. 2.149 Endometrial injury for pregnancy following sexual intercourse or intrauterine insemination
1317,CD011425,CD011425 v. 3.0 Computer and mobile technology interventions for self-management in chronic obstructive pulmonary di
1318,CD011426,CD011426 v. 2.2 Topical antibiotics for preventing surgical site infection in wounds healing by primary intention
1319,CD011432,CD011432 v. 2.2 Interventions to increase tuberculosis case detection at primary healthcare or community-level servi
1320,CD011434,CD011434 v. 2.4 Upper limb exercise training for COPD
1321,CD011436,CD011436 v. 5.0 The use of ultrasound guidance for perioperative neuraxial and peripheral nerve blocks in children
1322,CD011437,CD011437 v. 2.0 Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose 
1323,CD011438,CD011438 v. 3.0 Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of 
1324,CD011444,CD011444 v. 3.0 Mefloquine for preventing malaria in pregnant women
1325,CD011461,CD011461 v. 2.0 Molecular-targeted first-line therapy for advanced gastric cancer
1326,CD011462,CD011462 v. 3.0 Hypofractionation for clinically localized prostate cancer
1327,CD011466,CD011466 v. 1.126 Fluid restriction in the management of transient tachypnea of the newborn
1328,CD011469,CD011469 v. 3.0 Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus
1329,CD011478,CD011478 v. 2.0 Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for
1330,CD011479,CD011479 v. 2.5 Personalised digital interventions for reducing hazardous and harmful alcohol consumption in communi
1331,CD011481,CD011481 v. 2.0 Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users
1332,CD011491,CD011491 v. 2.2 Oxytocin for preventing postpartum haemorrhage (PPH) in non-facility birth settings
1333,CD011492,CD011492 v. 2.0 Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery
1334,CD011497,CD011497 v. 1.79 Physical activity for treatment of irritable bowel syndrome
1335,CD011498,CD011498 v. 2.0 Non-surgical versus surgical treatment for oesophageal cancer
1336,CD011504,CD011504 v. 3.0 Community-level interventions for improving access to food in low- and middle-income countries
1337,CD011505,CD011505 v. 3.0 Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of 
1338,CD011506,CD011506 v. 3.0 Cerebral near-infrared spectroscopy monitoring for prevention of brain injury in very preterm infant
1339,CD011507,CD011507 v. 4.6 Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes
1340,CD011511,CD011511 v. 6.19 Vitamin D for the management of asthma
1341,CD011513,CD011513 v. 2.39 Palliative care interventions in advanced dementia
1342,CD011516,CD011516 v. 5.0 Assessment and support during early labour for improving birth outcomes
1343,CD011518,CD011518 v. 2.2 Mindfulness-based stress reduction for women diagnosed with breast cancer
1344,CD011520,CD011520 v. 2.0 Vortioxetine for depression in adults
1345,CD011522,CD011522 v. 2.0 Pregabalin for decreasing pancreatic pain in chronic pancreatitis
1346,CD011525,CD011525 v. 2.5 Intermittent preventive treatment for malaria in infants
1347,CD011530,CD011530 v. 2.0 Antibiotics for preventing lower respiratory tract infections in high-risk children aged 12 years an
1348,CD011534,CD011534 v. 3.12 Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs alone or combined for pain re
1349,CD011535,CD011535 v. 15.18 Systemic pharmacological treatments for chronic plaque psoriasis a network meta-analysis
1350,CD011537,CD011537 v. 5.0 Intrauterine administration of human chorionic gonadotropin (hCG) for subfertile women undergoing as
1351,CD011542,CD011542 v. 2.0 Environmental and behavioural modifications for improving food and fluid intake in people with demen
1352,CD011545,CD011545 v. 1.143 Multi-professional simulation-based team training in obstetric emergencies for improving patient out
1353,CD011546,CD011546 v. 3.0 Pharmacological interventions for cognitive decline in people with Down syndrome
1354,CD011547,CD011547 v. 1.0 Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
1355,CD011552,CD011552 v. 3.0 Interventions for preventing oral mucositis in patients with cancer receiving treatment oral cryoth
1356,CD011556,CD011556 v. 3.13 Strategies to improve smoking cessation rates in primary care
1357,CD011563,CD011563 v. 1.101 Mesh fixation techniques in primary ventral or incisional hernia repair
1358,CD011564,CD011564 v. 3.4 Vitamin D supplementation for chronic liver diseases in adults
1359,CD011565,CD011565 v. 2.0 Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults
1360,CD011570,CD011570 v. 1.86 Specific psychological therapiesversus other therapies or no treatment for severe and enduring anor
1361,CD011572,CD011572 v. 2.0 Placebo response and remission rates in randomised trials of induction and maintenance therapy for u
1362,CD011574,CD011574 v. 2.582 Interventions for preventing falls in Parkinson's disease
1363,CD011583,CD011583 v. 2.0 Nut consumption for the primary prevention of cardiovascular disease
1364,CD011585,CD011585 v. 2.31 Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis
1365,CD011586,CD011586 v. 4.0 Antibiotics and antiseptics for pressure ulcers
1366,CD011589,CD011589 v. 1.249 Routine provision of feedback from patient-reported outcome measurements to healthcare providers and
1367,CD011594,CD011594 v. 2.0 Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease 
1368,CD011595,CD011595 v. 2.0 Mosquito repellents for malaria prevention
1369,CD011608,CD011608 v. 2.2 Nerve blocks or no nerve blocks for pain control after elective hip replacement (arthroplasty) surge
1370,CD011611,CD011611 v. 3.14 Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder
1371,CD011612,CD011612 v. 5.0 Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depres
1372,CD011616,CD011616 v. 2.0 Botulinum toxins for the prevention of migraine in adults
1373,CD011618,CD011618 v. 2.1 Return-to-work coordination programmes for improving return to work in workers on sick leave
1374,CD011620,CD011620 v. 2.0 Education of healthcare professionals for preventing pressure ulcers
1375,CD011621,CD011621 v. 10.4 Personal protective equipment for preventing highly infectious diseases due to exposure to contamina
1376,CD011640,CD011640 v. 3.0 Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD)
1377,CD011646,CD011646 v. 3.0 Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease)
1378,CD011651,CD011651 v. 3.0 School-based self-management interventions for asthma in children and adolescents a mixed methods s
1379,CD011660,CD011660 v. 2.0 Exercise interventions for cerebral palsy
1380,CD011671,CD011671 v. 2.0 Machine perfusion preservation versus static cold storage for deceased donor kidney transplantation
1381,CD011672,CD011672 v. 1.107 Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress synd
1382,CD011677,CD011677 v. 3.10 Strategies for enhancing the implementation of school-based policies or practices targeting diet ph
1383,CD011682,CD011682 v. 2.0 Self-management interventions including action plans for exacerbations versus usual care in patients
1384,CD011689,CD011689 v. 3.13 Uterotonic agents for preventing postpartum haemorrhage a network meta-analysis
1385,CD011695,CD011695 v. 4.0 Nutritional interventions for preventing stunting in children (birth to 59 months) living in urban s
1386,CD011710,CD011710 v. 4.5 Internet-based cognitive and behavioural therapies for post-traumatic stress disorder (PTSD) in adul
1387,CD011714,CD011714 v. 2.0 Home telemonitoring and remote feedback between clinic visits for asthma
1388,CD011719,CD011719 v. 3.0 Remote ischaemic preconditioning for coronary artery bypass grafting (with or without valve surgery)
1389,CD011723,CD011723 v. 2.8 Mindfulness-based interventions for substance use disorders
1390,CD011729,CD011729 v. 2.0 Client feedback in psychological therapy for children and adolescents with mental health problems
1391,CD011737,CD011737 v. 3.0 Reduction in saturated fat intake for cardiovascular disease
1392,CD011746,CD011746 v. 2.0 Gemcitabine-based chemotherapy for advanced biliary tract carcinomas
1393,CD011747,CD011747 v. 3.0 Ranolazine for stable angina pectoris
1394,CD011748,CD011748 v. 4.0 PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
1395,CD011756,CD011756 v. 2.0 Plasma transfusions prior to insertion of central lines for people with abnormal coagulation
1396,CD011761,CD011761 v. 2.0 Iodine supplementation for women during the preconception pregnancy and postpartum period
1397,CD011764,CD011764 v. 2.0 Neuromuscular electrical stimulation for the prevention of venous thromboembolism
1398,CD011768,CD011768 v. 2.6 Educational interventions for improving primary caregiver complementary feeding practices for childr
1399,CD011770,CD011770 v. 2.12 Dexamethasone as an adjuvant to peripheral nerve block
1400,CD011775,CD011775 v. 2.14 Child protection training for professionals to improve reporting of child abuse and neglect
1401,CD011779,CD011779 v. 3.4 Strategies to improve the implementation of healthy eating physical activity and obesity prevention
1402,CD011786,CD011786 v. 2.80 Chloral hydrate as a sedating agent for neurodiagnostic procedures in children
1403,CD011790,CD011790 v. 5.3 Pregabalin for pain in fibromyalgia in adults
1404,CD011798,CD011798 v. 2.0 Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
1405,CD011818,CD011818 v. 2.0 Cognitive behavioural therapy (CBT) for adults and adolescents with asthma
1406,CD011819,CD011819 v. 1.34 Stem cell transplantation for systemic sclerosis
1407,CD011821,CD011821 v. 3.0 Antiseptics for burns
1408,CD011822,CD011822 v. 2.0 Primary closure versus delayed or no closure for traumatic wounds due to mammalian bite
1409,CD011824,CD011824 v. 4.0 Amitriptyline for fibromyalgia in adults
1410,CD011825,CD011825 v. 2.0 Adverse events in people taking macrolide antibiotics versus placebo for any indication
1411,CD011841,CD011841 v. 2.0 Interventions for central serous chorioretinopathy a network meta-analysis
1412,CD011845,CD011845 v. 2.0 mHealth education interventions in heart failure
1413,CD011847,CD011847 v. 2.17 Electroconvulsive therapy for treatment-resistant schizophrenia
1414,CD011849,CD011849 v. 2.0 Psychological therapies for the treatment of mental disorders in low- and middle-income countries af
1415,CD011851,CD011851 v. 2.2 Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascula
1416,CD011860,CD011860 v. 2.0 Education and training for preventing and minimizing workplace aggression directed toward healthcare
1417,CD011866,CD011866 v. 2.0 Psychosocial interventions for psychostimulant misuse
1418,CD011883,CD011883 v. 2.4 Increasing antipsychotic dose for non response in schizophrenia
1419,CD011887,CD011887 v. 3.6 Action observation for upper limb rehabilitation after stroke
1420,CD011889,CD011889 v. 7.0 Paracetamol (acetaminophen) for acute treatment of episodic tension-type headache in adults
1421,CD011905,CD011905 v. 4.0 Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people 
1422,CD011906,CD011906 v. 3.0 Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people
1423,CD011913,CD011913 v. 4.4 Immediate versus delayed postpartum insertion of contraceptive implant and IUD for contraception
1424,CD011915,CD011915 v. 2.7 Adjunctive therapies in addition to land-based exercise therapy for osteoarthritis of the hip or kne
1425,CD011918,CD011918 v. 3.0 Protease-modulating matrix treatments for healing venous leg ulcers
1426,CD011921,CD011921 v. 3.0 Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants
1427,CD011931,CD011931 v. 2.0 Pharmacological interventions for the prevention of acute postoperative pain in adults following bra
1428,CD011946,CD011946 v. 3.0 Interventions for acne scars
1429,CD011947,CD011947 v. 2.0 Dressings and topical agents for treating pressure ulcers
1430,CD011952,CD011952 v. 2.0 Ascorbic acid for the treatment of Charcot-Marie-Tooth disease
1431,CD011969,CD011969 v. 2.0 Deprescribing versus continuation of chronic proton pump inhibitor use in adults
1432,CD011970,CD011970 v. 2.0 Lifestyle interventions for the treatment of women with gestational diabetes
1433,CD011971,CD011971 v. 2.0 Antihypertensive withdrawal for the prevention of cognitive decline
1434,CD011976,CD011976 v. 5.2 Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults
1435,CD011983,CD011983 v. 2.0 Supervised dosing with a long-acting opioid medication in the management of opioid dependence
1436,CD011986,CD011986 v. 3.0 Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vess
1437,CD011989,CD011989 v. 2.0 Patient-controlled analgesia with remifentanil versus alternative parenteral methods for pain manage
1438,CD011990,CD011990 v. 3.0 Interventions for preventing oral mucositis in patients with cancer receiving treatment cytokines a
1439,CD012003,CD012003 v. 2.0 Breastfeeding education and support for women with twins or higher order multiples
1440,CD012004,CD012004 v. 3.0 Motor control exercise for chronic non-specific low-back pain
1441,CD012005,CD012005 v. 2.0 Interventions for fatigue in inflammatory bowel disease
1442,CD012006,CD012006 v. 2.1 Patient and lay carer education for preventing pressure ulceration in at-risk populations
1443,CD012007,CD012007 v. 3.12 Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epitheli
1444,CD012008,CD012008 v. 1.1 Parent-only interventions for childhood overweight or obesity in children aged 5 to 11 years
1445,CD012013,CD012013 v. 2.3 Interventions for self-harm in children and adolescents
1446,CD012020,CD012020 v. 5.3 Preoperative exercise training for people with non-small cell lung cancer
1447,CD012025,CD012025 v. 2.0 Brief educational strategies for improving contraception use in young people
1448,CD012026,CD012026 v. 1.207 Interventions for improving health literacy in people with chronic kidney disease
1449,CD012031,CD012031 v. 3.0 Bed rest with and without hospitalisation in multiple pregnancy for improving perinatal outcomes
1450,CD012032,CD012032 v. 2.4 Reconstructive surgery for treating pressure ulcers
1451,CD012033,CD012033 v. 6.0 Perioperative intravenous ketamine for acute postoperative pain in adults
1452,CD012035,CD012035 v. 3.0 Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopen
1453,CD012037,CD012037 v. 2.0 Insulin for the treatment of women with gestational diabetes
1454,CD012039,CD012039 v. 3.14 Pharmacotherapy for hypertension-induced left ventricular hypertrophy
1455,CD012042,CD012042 v. 2.0 Providing physicians with feedback on medication adherence for people with chronic diseases taking l
1456,CD012051,CD012051 v. 3.0 Interventions for treating persistent pain in survivors of torture
1457,CD012052,CD012052 v. 2.0 Yoga versus non-standard care for schizophrenia
1458,CD012055,CD012055 v. 4.0 Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with throm
1459,CD012057,CD012057 v. 3.0 Acupuncture for neuropathic pain in adults
1460,CD012058,CD012058 v. 2.0 Gene therapy for peripheral arterial disease
1461,CD012059,CD012059 v. 3.0 Desmopressin for treating nocturia in men
1462,CD012078,CD012078 v. 2.0 Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma
1463,CD012079,CD012079 v. 3.0 Transvaginal mesh or grafts compared with native tissue repair for vaginal prolapse
1464,CD012081,CD012081 v. 4.8 Psychological treatments for people with epilepsy
1465,CD012088,CD012088 v. 3.0 Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation
1466,CD012093,CD012093 v. 2.0 Topical and device-based treatments for fungal infections of the toenails
1467,CD012095,CD012095 v. 2.0 Celecoxib for rheumatoid arthritis
1468,CD012099,CD012099 v. 2.0 Interventions for supporting the initiation and continuation of breastfeeding among women who are ov
1469,CD012105,CD012105 v. 1.1 Diet physical activity and behavioural interventions for the treatment of overweight or obesity in
1470,CD012110,CD012110 v. 3.0 Body weight management in overweight and obese breast cancer survivors
1471,CD012116,CD012116 v. 2.2 Acetylsalicylic acid (aspirin) for schizophrenia
1472,CD012119,CD012119 v. 5.0 Emollients and moisturisers for eczema
1473,CD012120,CD012120 v. 2.0 Physical exercise training for type 3 spinal muscular atrophy
1474,CD012123,CD012123 v. 2.0 N-acetylcysteine for non-paracetamol (acetaminophen)-related acute liver failure
1475,CD012124,CD012124 v. 3.0 Subcuticular sutures for skin closure in non-obstetric surgery
1476,CD012128,CD012128 v. 2.0 Surgical interventions for symptomatic mild to moderate knee osteoarthritis
1477,CD012132,CD012132 v. 2.0 Organisation of health services for preventing and treating pressure ulcers
1478,CD012152,CD012152 v. 2.59 Oral dextrose gel to prevent hypoglycaemia in at-risk neonates
1479,CD012155,CD012155 v. 4.0 Interventions with pregnant women new mothers and other primary caregivers for preventing early chi
1480,CD012157,CD012157 v. 2.173 Antidepressants for hip and knee osteoarthritis
1481,CD012158,CD012158 v. 2.0 Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease
1482,CD012177,CD012177 v. 3.0 The effects of interactive training of healthcare providers on the management of life-threatening em
1483,CD012182,CD012182 v. 4.0 Cannabis-based medicines for chronic neuropathic pain in adults
1484,CD012189,CD012189 v. 1.20 Psychosocial interventions for self-harm in adults
1485,CD012197,CD012197 v. 3.0 Pharmacological interventions for apathy in Alzheimer's disease
1486,CD012199,CD012199 v. 2.8 Interventions to improve water sanitation and hygiene for preventing soil-transmitted helminth inf
1487,CD012204,CD012204 v. 2.2 Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention o
1488,CD012206,CD012206 v. 1.164 Non-surgical therapies for Peyronie's disease
1489,CD012208,CD012208 v. 2.4 Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascu
1490,CD012212,CD012212 v. 3.0 Supplemental perioperative intravenous crystalloids for postoperative nausea and vomiting
1491,CD012213,CD012213 v. 2.3 Interventions for managing halitosis
1492,CD012221,CD012221 v. 2.0 Multifactorial and multiple component interventions for preventing falls in older people living in t
1493,CD012224,CD012224 v. 1.0 Manual therapy and exercise for rotator cuff disease
1494,CD012225,CD012225 v. 1.0 Electrotherapy modalities for rotator cuff disease
1495,CD012226,CD012226 v. 3.0 Interventions to improve adherence to inhaled steroids for asthma
1496,CD012229,CD012229 v. 4.0 Ghrelin for the management of cachexia associated with cancer
1497,CD012232,CD012232 v. 4.0 Single fixed-dose oral dexketoprofen plus tramadol for acute postoperative pain in adults
1498,CD012235,CD012235 v. 2.0 Interventions for ulceration and other skin changes caused by nerve damage in leprosy
1499,CD012236,CD012236 v. 2.12 Interventions for prodromal stage of psychosis
1500,CD012241,CD012241 v. 3.0 Education of family members to support weaning to solids and nutrition in later infancy in term-born
1501,CD012243,CD012243 v. 2.2 Workplace lighting for improving alertness and mood in daytime workers
1502,CD012247,CD012247 v. 4.0 Buffered solutions versus 0.9 saline for resuscitation in critically ill adults and children
1503,CD012249,CD012249 v. 1.62 School-based interventions for improving contraceptive use in adolescents
1504,CD012250,CD012250 v. 1.457 Circumcision devices versus standard surgical techniques in adolescent and adult male circumcisions
1505,CD012254,CD012254 v. 2.0 Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders
1506,CD012256,CD012256 v. 3.0 Final-impression techniques and materials for making complete and removable partial dentures
1507,CD012269,CD012269 v. 1.72 Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimag
1508,CD012270,CD012270 v. 2.6 Iridotomy to slow progression of visual field loss in angle-closure glaucoma
1509,CD012277,CD012277 v. 4.0 Computerised cognitive training for 12 or more weeks for maintaining cognitive function in cognitive
1510,CD012279,CD012279 v. 2.6 Computerised cognitive training for preventing dementia in people with mild cognitive impairment
1511,CD012280,CD012280 v. 3.2 Exercise interventions for people undergoing multimodal cancer treatment that includes surgery
1512,CD012286,CD012286 v. 2.3 Interventions to improve inhaler technique for people with asthma
1513,CD012287,CD012287 v. 2.0 Family-based prevention programmes for alcohol use in young people
1514,CD012290,CD012290 v. 2.6 Active mind-body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation 
1515,CD012292,CD012292 v. 2.0 Environmental interventions to reduce the consumption of sugar-sweetened beverages and their effects
1516,CD012295,CD012295 v. 3.0 Psychological therapies for the prevention of migraine in adults
1517,CD012300,CD012300 v. 2.3 Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic 
1518,CD012305,CD012305 v. 2.0 Antimicrobial agents for preventing urinary tract infections in adults undergoing cystoscopy
1519,CD012317,CD012317 v. 3.0 Intravenous versus inhalational maintenance of anaesthesia for postoperative cognitive outcomes in e
1520,CD012324,CD012324 v. 2.0 Communication interventions for autism spectrum disorder in minimally verbal children
1521,CD012331,CD012331 v. 2.0 Lay-led and peer support interventions for adolescents with asthma
1522,CD012334,CD012334 v. 4.0 Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encep
1523,CD012336,CD012336 v. 1.61 Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to b
1524,CD012345,CD012345 v. 5.0 Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
1525,CD012347,CD012347 v. 3.0 Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease
1526,CD012348,CD012348 v. 2.12 Video feedback for parental sensitivity and attachment security in children under five years
1527,CD012349,CD012349 v. 2.11 Interventions for improving adherence to iron chelation therapy in people with sickle cell disease o
1528,CD012355,CD012355 v. 2.0 Once-daily long-acting beta-agonistsinhaled corticosteroids combined inhalers versus inhaled long-
1529,CD012358,CD012358 v. 1.89 Expanded polytetrafluoroethylene (ePTFE)-covered stents versus bare stents for transjugular intrahep
1530,CD012367,CD012367 v. 3.0 Conservative interventions for treating functional daytime urinary incontinence in children
1531,CD012368,CD012368 v. 2.0 Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 d
1532,CD012370,CD012370 v. 2.0 Hospitalisation in short-stay units for adults with internal medicine diseases and conditions
1533,CD012371,CD012371 v. 1.0 Psychological therapies for children and adolescents exposed to trauma
1534,CD012379,CD012379 v. 2.3 eHealth interventions for people with chronic kidney disease
1535,CD012380,CD012380 v. 2.10 Interventions for chronic kidney disease in people with sickle cell disease
1536,CD012389,CD012389 v. 3.3 Interventions for preventing silent cerebral infarcts in people with sickle cell disease
1537,CD012390,CD012390 v. 2.0 Electrical stimulation with non-implanted devices for stress urinary incontinence in women
1538,CD012406,CD012406 v. 4.0 Macrolide antibiotics for bronchiectasis
1539,CD012414,CD012414 v. 2.0 Penile rehabilitation for postprostatectomy erectile dysfunction
1540,CD012416,CD012416 v. 2.7 Oral care measures for preventing nursing home-acquired pneumonia
1541,CD012417,CD012417 v. 2.15 Psychological and social interventions for the prevention of mental disorders in people living in lo
1542,CD012418,CD012418 v. 2.0 Interventions for improving medical students' interpersonal communication in medical consultations
1543,CD012419,CD012419 v. 2.0 Interventions for improving medication-taking ability and adherence in older adults prescribed multi
1544,CD012421,CD012421 v. 1.4 Surgical options for lumbar spinal stenosis
1545,CD012423,CD012423 v. 1.137 Training healthcare providers to respond to intimate partner violence against women
1546,CD012424,CD012424 v. 2.0 Exercise for preventing falls in older people living in the community
1547,CD012425,CD012425 v. 2.2 Follow-up strategies following completion of primary cancer treatment in adult cancer survivors
1548,CD012433,CD012433 v. 3.0 Oxcarbazepine add-on for drug-resistant focal epilepsy
1549,CD012436,CD012436 v. 2.2 Drug interventions for the treatment of obesity in children and adolescents
1550,CD012442,CD012442 v. 2.0 Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuro
1551,CD012450,CD012450 v. 2.3 Systemic corticosteroids for radicular and non-radicular low back pain
1552,CD012453,CD012453 v. 2.0 Topical and systemic antifungal therapy for chronic rhinosinusitis
1553,CD012455,CD012455 v. 4.0 Melatonin for the promotion of sleep in adults in the intensive care unit
1554,CD012462,CD012462 v. 3.0 Nasal decontamination for the prevention of surgical site infection in Staphylococcus aureus carrier
1555,CD012463,CD012463 v. 2.5 Family-centred interventions for Indigenous early childhood well-being by primary healthcare service
1556,CD012466,CD012466 v. 2.6 Pharmacological interventions for heart failure in people with chronic kidney disease
1557,CD012467,CD012467 v. 4.0 Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous r
1558,CD012471,CD012471 v. 2.0 Information or education interventions for adult intensive care unit (ICU) patients and their carers
1559,CD012472,CD012472 v. 4.0 Patient-mediated interventions to improve professional practice
1560,CD012473,CD012473 v. 3.0 Probiotics to prevent infantile colic
1561,CD012479,CD012479 v. 1.250 Rehabilitation following surgery for flexor tendon injuries of the hand
1562,CD012484,CD012484 v. 3.0 Beta-blockers for suspected or diagnosed acute myocardial infarction
1563,CD012485,CD012485 v. 3.0 Comprehensive geriatric assessment for older people admitted to a surgical service
1564,CD012487,CD012487 v. 3.0 Workplace interventions for increasing standing or walking for decreasing musculoskeletal symptoms i
1565,CD012488,CD012488 v. 3.0 Psychological therapies for anxiety and depression in children and adolescents with long-term physic
1566,CD012489,CD012489 v. 3.0 E-Health interventions for anxiety and depression in children and adolescents with long-term physica
1567,CD012502,CD012502 v. 2.0 Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events
1568,CD012510,CD012510 v. 2.0 Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent r
1569,CD012513,CD012513 v. 2.4 Interventions for weight reduction in obesity to improve survival in women with endometrial cancer
1570,CD012515,CD012515 v. 1.50 Training health workers in clinical breast examination for early detection of breast cancer in low- 
1571,CD012522,CD012522 v. 2.4 Negative pressure wound therapy for open traumatic wounds
1572,CD012527,CD012527 v. 2.0 Psychological interventions to foster resilience in healthcare professionals
1573,CD012529,CD012529 v. 4.0 Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for p
1574,CD012533,CD012533 v. 2.0 Telephone interventions delivered by healthcare professionals for providing education and psychoso
1575,CD012536,CD012536 v. 8.0 Antiepileptic drugs for chronic non-cancer pain in children and adolescents
1576,CD012547,CD012547 v. 2.2 Caregiver involvement in interventions for improving children's dietary intake and physical activity
1577,CD012551,CD012551 v. 3.0 Non-pharmacological interventions for treating chronic prostatitischronic pelvic pain syndrome
1578,CD012552,CD012552 v. 2.0 Pharmacological interventions for treating chronic prostatitischronic pelvic pain syndrome
1579,CD012554,CD012554 v. 2.0 Interventions outside the workplace for reducing sedentary behaviour in adults under 60 years of age
1580,CD012555,CD012555 v. 2.0 Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults
1581,CD012556,CD012556 v. 2.0 Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)
1582,CD012557,CD012557 v. 2.8 Baclofen for alcohol use disorder
1583,CD012565,CD012565 v. 1.45 Beta-blockers in patients without heart failure after myocardial infarction
1584,CD012566,CD012566 v. 2.0 Rinse-free hand wash for reducing absenteeism among preschool and school children
1585,CD012568,CD012568 v. 2.0 Adjunctive systemic antimicrobials for the non-surgical treatment of periodontitis
1586,CD012583,CD012583 v. 2.0 Dressings and topical agents for treating venous leg ulcers
1587,CD012595,CD012595 v. 4.5 School dental screening programmes for oral health
1588,CD012607,CD012607 v. 1.90 Totally tubeless tubeless and tubed percutaneous nephrolithotomy for treating kidney stones
1589,CD012610,CD012610 v. 2.2 Lipid-based nutrient supplements for maternal birth and infant developmental outcomes
1590,CD012611,CD012611 v. 4.0 Preventive lipid-based nutrient supplements given with complementary foods to infants and young chil
1591,CD012614,CD012614 v. 2.0 Cognitive behavioural therapy for tinnitus
1592,CD012615,CD012615 v. 2.0 Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
1593,CD012620,CD012620 v. 2.0 Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary 
1594,CD012621,CD012621 v. 3.0 Phosphodiesterase 5 inhibitors for pulmonary hypertension
1595,CD012622,CD012622 v. 2.0 Non-pharmacological interventions for chronic pain in multiple sclerosis
1596,CD012624,CD012624 v. 2.0 Pre-emptive and preventive opioids for postoperative pain in adults undergoing all types of surgery
1597,CD012625,CD012625 v. 5.0 Interventions for improving sleep quality in people with chronic kidney disease
1598,CD012626,CD012626 v. 2.0 Interventions for promoting physical activity in people with chronic obstructive pulmonary disease (
1599,CD012633,CD012633 v. 2.6 Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents 
1600,CD012651,CD012651 v. 1.0 Diet physical activity and behavioural interventions for the treatment of overweight or obese child
1601,CD012652,CD012652 v. 5.3 Educational interventions for health professionals managing chronic obstructive pulmonary disease in
1602,CD012658,CD012658 v. 2.0 Levonorgestrel-releasing intrauterine system for endometrial hyperplasia
1603,CD012659,CD012659 v. 2.2 Real-time video counselling for smoking cessation
1604,CD012662,CD012662 v. 2.0 Organisational interventions for preventing and minimising aggression directed towards healthcare wo
1605,CD012670,CD012670 v. 2.3 Benzodiazepines for treatment of patients with delirium excluding those who are cared for in an inte
1606,CD012675,CD012675 v. 3.0 Mobile phone-based interventions for improving adherence to medication prescribed for the primary pr
1607,CD012681,CD012681 v. 2.0 Severe fatigue after treatment for childhood cancer
1608,CD012687,CD012687 v. 1.187 Wavefront excimer laser refractive surgery for adults with refractive errors
1609,CD012688,CD012688 v. 4.8 Indoor residual spraying for preventing malaria in communities using insecticide-treated nets
1610,CD012691,CD012691 v. 1.6 Diet physical activity and behavioural interventions for the treatment of overweight or obese adole
1611,CD012692,CD012692 v. 2.0 Interventions for unexplained infertility a systematic review and network meta-analysis
1612,CD012697,CD012697 v. 1.14 Magnetic seizure therapy for people with schizophrenia
1613,CD012700,CD012700 v. 1.0 Aerobic exercise training for adults with fibromyalgia
1614,CD012704,CD012704 v. 3.0 Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults
1615,CD012705,CD012705 v. 1.30 Comprehensive Geriatric Assessment for community-dwelling high-risk frail older people
1616,CD012707,CD012707 v. 1.123 Adult patient access to electronic health records
1617,CD012708,CD012708 v. 4.0 Mirtazapine for fibromyalgia in adults
1618,CD012720,CD012720 v. 1.89 Kinesio taping for rotator cuff disease
1619,CD012721,CD012721 v. 2.78 Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure w
1620,CD012735,CD012735 v. 3.0 Pitavastatin for lowering lipids
1621,CD012739,CD012739 v. 2.0 Setting and techniques for monitoring blood pressure during pregnancy
1622,CD012743,CD012743 v. 2.0 Ab interno trabecular bypass surgery with iStent for open-angle glaucoma
1623,CD012745,CD012745 v. 2.0 Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant u
1624,CD012753,CD012753 v. 2.0 Xenon as an adjuvant to therapeutic hypothermia in near-term and term newborns with hypoxic-ischaemi
1625,CD012754,CD012754 v. 2.0 Uterotonic agents for first-line treatment of postpartum haemorrhage a network meta-analysis
1626,CD012760,CD012760 v. 2.0 Families and Schools Together (FAST) for improving outcomes for children and their families
1627,CD012763,CD012763 v. 2.0 Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults
1628,CD012767,CD012767 v. 2.15 Perioperative restrictive versus goal-directed fluid therapy for adults undergoing major non-cardiac
1629,CD012774,CD012774 v. 2.8 Fecal transplantation for treatment of inflammatory bowel disease
1630,CD012775,CD012775 v. 3.0 Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogen
1631,CD012780,CD012780 v. 2.0 The effectiveness and cost-effectiveness of hospital-based specialist palliative care for adults wit
1632,CD012786,CD012786 v. 2.0 Exercise-based cardiac rehabilitation for adults with stable angina
1633,CD012787,CD012787 v. 2.0 Effect of alcohol on blood pressure
1634,CD012788,CD012788 v. 2.2 Intraoperative imaging technology to maximise extent of resection for glioma
1635,CD012796,CD012796 v. 2.0 Targeted therapy for metastatic renal cell carcinoma
1636,CD012799,CD012799 v. 1.79 Selective serotonin re-uptake inhibitors for premature ejaculation in adult men
1637,CD012815,CD012815 v. 6.1 Marine-derived n-3 fatty acids therapy for stroke
1638,CD012817,CD012817 v. 1.68 Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer
1639,CD012820,CD012820 v. 1.39 Cannabinoids for the treatment of dementia
1640,CD012823,CD012823 v. 1.101 Effectiveness of psychosocial interventions for reducing parental substance misuse
1641,CD012829,CD012829 v. 3.0 Interventions to increase patient and family involvement in escalation of care for acute life-threat
1642,CD012830,CD012830 v. 1.184 Pharmacologic interventions for mydriasis in cataract surgery
1643,CD012839,CD012839 v. 2.0 Dietary interventions for induction and maintenance of remission in inflammatory bowel disease
1644,CD012843,CD012843 v. 5.3 Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery
1645,CD012844,CD012844 v. 2.0 Video games for people with schizophrenia
1646,CD012849,CD012849 v. 1.111 Probiotics for management of functional abdominal pain disorders in children
1647,CD012854,CD012854 v. 1.101 Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipi
1648,CD012856,CD012856 v. 3.0 Screening hysteroscopy in subfertile women and women undergoing assisted reproduction
1649,CD012859,CD012859 v. 3.0 Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia a networ
1650,CD012864,CD012864 v. 2.0 Physical activity interventions for disease-related physical and mental health during and following 
1651,CD012867,CD012867 v. 6.2 Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign
1652,CD012874,CD012874 v. 2.21 Tourniquet use for knee replacement surgery
1653,CD012875,CD012875 v. 3.0 Effects of oral vitamin D supplementation on linear growth and other health outcomes among children 
1654,CD012880,CD012880 v. 4.0 Alcoholics Anonymous and other 12-step programs for alcohol use disorder
1655,CD012882,CD012882 v. 3.3 Integrated community case management of childhood illness in low- and middle-income countries
1656,CD012885,CD012885 v. 2.0 Non-nutritive sweeteners for diabetes mellitus
1657,CD012908,CD012908 v. 2.24 Non-pharmacological interventions for sleep promotion in hospitalized children
1658,CD012915,CD012915 v. 2.0 MVA85A vaccine to enhance BCG for preventing tuberculosis
1659,CD012918,CD012918 v. 2.0 Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis
1660,CD012927,CD012927 v. 2.36 Mobile technologies to support healthcare provider to healthcare provider communication and manageme
1661,CD012930,CD012930 v. 2.0 Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler v
1662,CD012932,CD012932 v. 2.2 Behavioural interventions delivered through interactive social media for health behaviour change he
1663,CD012936,CD012936 v. 2.0 Palliative care interventions for people with multiple sclerosis
1664,CD012937,CD012937 v. 2.10 Routine monitoring of gastric residual for prevention of necrotising enterocolitis in preterm infant
1665,CD012944,CD012944 v. 2.1 Decision-support tools via mobile devices to improve quality of care in primary healthcare settings
1666,CD012946,CD012946 v. 3.0 Laser-assisted in-situ keratomileusis (LASIK) with a mechanical microkeratome compared to LASIK with
1667,CD012949,CD012949 v. 2.0 Probiotics for people with cystic fibrosis
1668,CD012955,CD012955 v. 4.0 Psychological therapies for people with borderline personality disorder
1669,CD012956,CD012956 v. 1.125 Pharmacological interventions for people with borderline personality disorder
1670,CD012962,CD012962 v. 2.0 Rapid initiation of antiretroviral therapy for people living with HIV
1671,CD012970,CD012970 v. 2.0 Probiotic treatment for women with gestational diabetes to improve maternal and infant health and we
1672,CD012975,CD012975 v. 1.0 Surgery for women with posterior compartment prolapse
1673,CD012978,CD012978 v. 1.213 Pre-emptive and preventive NSAIDs for postoperative pain in adults undergoing all types of surgery
1674,CD012982,CD012982 v. 3.0 Death audits and reviews for reducing maternal perinatal and child mortality
1675,CD012988,CD012988 v. 2.0 Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms i
1676,CD012990,CD012990 v. 2.0 GLP-1 receptor agonists for Parkinson's disease
1677,CD012991,CD012991 v. 2.0 Motor neuroprosthesis for promoting recovery of function after stroke
1678,CD012994,CD012994 v. 1.2 Ivermectin and permethrin for treating scabies
1679,CD012996,CD012996 v. 2.34 Interventions for reducing sedentary behaviour in people with stroke
1680,CD012998,CD012998 v. 1.114 Roux-en-Y versus Billroth-I reconstruction after distal gastrectomy for gastric cancer
1681,CD013004,CD013004 v. 2.0 Ivabradine as adjuvant treatment for chronic heart failure
1682,CD013017,CD013017 v. 2.2 Psychological therapies for women who experience intimate partner violence
1683,CD013019,CD013019 v. 2.0 Motor imagery for gait rehabilitation after stroke
1684,CD013020,CD013020 v. 3.0 Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases a networ
1685,CD013022,CD013022 v. 2.0 Advance care planning for adults with heart failure
1686,CD013024,CD013024 v. 3.0 Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease
1687,CD013030,CD013030 v. 2.11 Digital interventions to improve adherence to maintenance medication in asthma
1688,CD013035,CD013035 v. 1.198 Parathyroidectomy for adults with primary hyperparathyroidism
1689,CD013039,CD013039 v. 2.13 Interventions for treating cavitated or dentine carious lesions
1690,CD013040,CD013040 v. 1.193 Telerehabilitation for chronic respiratory disease
1691,CD013046,CD013046 v. 1.101 Vitamin D supplementation for term breastfed infants to prevent vitamin D deficiency and improve bon
1692,CD013052,CD013052 v. 2.1 Systemic antibiotics for chronic suppurative otitis media
1693,CD013054,CD013054 v. 2.0 Topical antibiotics with steroids for chronic suppurative otitis media
1694,CD013069,CD013069 v. 2.0 Cognitive training for people with mild to moderate dementia
1695,CD013070,CD013070 v. 1.30 Stem cell transplantation for induction of remission in medically refractory Crohns disease
1696,CD013074,CD013074 v. 1.114 Interventions for fatigue in people with kidney failure requiring dialysis
1697,CD013084,CD013084 v. 2.14 Intravenous iron therapy for non-anaemic iron-deficient adults
1698,CD013088,CD013088 v. 3.64 Case management for integrated care of older people with frailty in community settings
1699,CD013098,CD013098 v. 2.9 Self-certification versus physician certification of sick leave for reducing sickness absence and as
1700,CD013102,CD013102 v. 2.0 Pharmacist services for non-hospitalised patients
1701,CD013105,CD013105 v. 1.0 Perioperative interventions in pelvic organ prolapse surgery
1702,CD013108,CD013108 v. 1.0 Surgery for women with pelvic organ prolapse with or without stress urinary incontinence
1703,CD013109,CD013109 v. 1.186 Aldosterone antagonists for people with chronic kidney disease requiring dialysis
1704,CD013110,CD013110 v. 2.0 Exercise training for bronchiectasis
1705,CD013116,CD013116 v. 4.10 Interventions for interpersonal communication about end of life care between health practitioners an
1706,CD013117,CD013117 v. 1.103 Ivermectin treatment in humans for reducing malaria transmission
1707,CD013119,CD013119 v. 1.102 Interventions for weight loss in people with chronic kidney disease who are overweight or obese
1708,CD013123,CD013123 v. 2.0 Treatment for ascites in adults with decompensated liver cirrhosis a network meta-analysis
1709,CD013124,CD013124 v. 3.0 Interventions for involving older patients with multi-morbidity in decision-making during primary ca
1710,CD013125,CD013125 v. 2.0 Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis 
1711,CD013127,CD013127 v. 1.77 Mental Health First Aid as a tool for improving mental health and well-being
1712,CD013136,CD013136 v. 2.11 Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder an
1713,CD013152,CD013152 v. 2.0 Health-improving interventions for obtaining employment in unemployed job seekers
1714,CD013156,CD013156 v. 2.19 Lifestyle modifications for nonalcohol-related fatty liver disease a network meta-analysis
1715,CD013157,CD013157 v. 2.20 Nutritional supplementation for nonalcohol-related fatty liver disease a network meta-analysis
1716,CD013162,CD013162 v. 2.0 Cognitive behavioural therapy for anxiety disorders in children and adolescents
1717,CD013163,CD013163 v. 2.2 Lipid emulsions for parenterally fed preterm infants
1718,CD013165,CD013165 v. 2.0 Potassium binders for chronic hyperkalaemia in people with chronic kidney disease
1719,CD013167,CD013167 v. 1.24 Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms i
1720,CD013169,CD013169 v. 1.255 Non-invasive positive airway pressure therapy for improving erectile dysfunction in men with obstruc
1721,CD013170,CD013170 v. 1.48 Cough augmentation techniques for people with chronic neuromuscular disorders
1722,CD013171,CD013171 v. 2.2 Lipid emulsions for parenterally fed term and late preterm infants
1723,CD013176,CD013176 v. 2.11 Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage
1724,CD013178,CD013178 v. 1.131 Interventions for people with type 2 diabetes mellitus fasting during Ramadan
1725,CD013183,CD013183 v. 2.0 Smoking reduction interventions for smoking cessation
1726,CD013196,CD013196 v. 2.12 Telehealth interventions remote monitoring and consultations for people with chronic obstructive pu
1727,CD013198,CD013198 v. 1.246 Prophylactic antibiotics for adults with chronic obstructive pulmonary disease a network meta-analy
1728,CD013203,CD013203 v. 2.0 Induction immunosuppression in adults undergoing liver transplantation a network meta-analysis
1729,CD013206,CD013206 v. 2.0 Systemic treatments for eczema a network meta-analysis
1730,CD013210,CD013210 v. 2.0 Interventions for maintenance of surgically induced remission in Crohns disease a network meta-ana
1731,CD013230,CD013230 v. 3.0 First aid interventions by laypeople for acute oral poisoning
1732,CD013238,CD013238 v. 5.0 Anti-epidermal growth factor receptor therapy for glioblastoma in adults
1733,CD013242,CD013242 v. 1.123 Pre-deployment programmes for building resilience in military and frontline emergency service person
1734,CD013244,CD013244 v. 1.11 Blue-light filtering spectacle lenses for visual performance sleep and macular health in adults
1735,CD013246,CD013246 v. 2.0 Digital interventions for the management of chronic obstructive pulmonary disease
1736,CD013247,CD013247 v. 2.12 Ocrelizumab for multiple sclerosis
1737,CD013252,CD013252 v. 3.2 Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention a netw
1738,CD013258,CD013258 v. 2.11 Environmental interventions for preventing falls in older people living in the community
1739,CD013272,CD013272 v. 1.0 Competitions for smoking cessation
1740,CD013276,CD013276 v. 1.29 Physiological track-and-triggerearly warning systems for use in maternity care
1741,CD013277,CD013277 v. 2.7 Sunlight for the prevention and treatment of hyperbilirubinemia in term and late preterm neonates
1742,CD013281,CD013281 v. 1.113 Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-inco
1743,CD013287,CD013287 v. 4.0 Specialised early intervention teams (extended time) for recent-onset psychosis
1744,CD013288,CD013288 v. 4.0 Specialised early intervention teams for recent-onset psychosis
1745,CD013299,CD013299 v. 3.0 Pharmacy-based management for depression in adults
1746,CD013305,CD013305 v. 3.0 Behavioural activation therapy for depression in adults
1747,CD013306,CD013306 v. 1.120 Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments a network 
1748,CD013307,CD013307 v. 4.3 Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients
1749,CD013308,CD013308 v. 1.6 Different doses durations and modes of delivery of nicotine replacement therapy for smoking cessati
1750,CD013309,CD013309 v. 2.7 Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants
1751,CD013315,CD013315 v. 1.4 Interventions for preventing high altitude illness Part 3. Miscellaneous and non-pharmacological in
1752,CD013318,CD013318 v. 1.13 Fenofibrate for diabetic retinopathy
1753,CD013319,CD013319 v. 2.6 Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic s
1754,CD013320,CD013320 v. 3.9 High versus low-added sugar consumption for the primary prevention of cardiovascular disease
1755,CD013321,CD013321 v. 2.0 Interventions for fear of childbirth including tocophobia
1756,CD013323,CD013323 v. 2.8 Non-Chinese herbal medicines for functional dyspepsia
1757,CD013325,CD013325 v. 2.3 Interventions for treating people with symptoms of bladder pain syndrome a network meta-analysis
1758,CD013327,CD013327 v. 2.12 Upper limb exercise for arteriovenous fistula maturation in people requiring permanent haemodialysis
1759,CD013328,CD013328 v. 2.10 Interventions to improve sanitation for preventing diarrhoea
1760,CD013333,CD013333 v. 3.0 Tea tree oil for Demodex blepharitis
1761,CD013334,CD013334 v. 3.7 Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk
1762,CD013348,CD013348 v. 3.2 Vascular endothelial growth factor (VEGF) targeting therapy for persistent recurrent or metastatic
1763,CD013350,CD013350 v. 1.155 Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income
1764,CD013356,CD013356 v. 10.0 Strategies for using topical corticosteroids in children and adults with eczema
1765,CD013365,CD013365 v. 1.69 Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large 
1766,CD013367,CD013367 v. 1.139 Humour-based interventions for people with schizophrenia
1767,CD013368,CD013368 v. 1.92 Running shoes for preventing lower limb running injuries in adults
1768,CD013373,CD013373 v. 2.12 Effects of consumers and health providers working in partnership on health services planning delive
1769,CD013376,CD013376 v. 2.0 Agricultural and nutritional education interventions for reducing aflatoxin exposure to improve infa
1770,CD013379,CD013379 v. 1.47 Interventions to enable communication for adult patients requiring an artificial airway with or with
1771,CD013381,CD013381 v. 3.0 Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary dise
1772,CD013382,CD013382 v. 1.33 Best first-line therapy for people with advanced non-small cell lung cancer performance status 2 wi
1773,CD013385,CD013385 v. 2.10 Decision coaching for people making healthcare decisions
1774,CD013393,CD013393 v. 2.0 Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults
1775,CD013398,CD013398 v. 3.25 House modifications for preventing malaria
1776,CD013403,CD013403 v. 1.9 Interventions for the long-term prevention of hereditary angioedema attacks
1777,CD013404,CD013404 v. 2.10 Surgical interventions for treating intracapsular hip fractures in older adults a network meta-anal
1778,CD013410,CD013410 v. 1.158 Arthroplasties for hip fracture in adults
1779,CD013413,CD013413 v. 2.0 Interventions to reduce tobacco use in people experiencing homelessness
1780,CD013419,CD013419 v. 1.0 Flexibility exercise training for adults with fibromyalgia
1781,CD013433,CD013433 v. 1.144 Stem cell therapy for dilated cardiomyopathy
1782,CD013435,CD013435 v. 2.0 Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergo
1783,CD013438,CD013438 v. 1.0 Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergo
1784,CD013441,CD013441 v. 2.10 Individual-level interventions to reduce personal exposure to outdoor air pollution and their effect
1785,CD013443,CD013443 v. 2.10 Early pharmacological interventions for universal prevention of post-traumatic stress disorder (PTSD
1786,CD013446,CD013446 v. 1.9 Regimens of vitamin D supplementation for women during pregnancy
1787,CD013457,CD013457 v. 1.135 The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communica
1788,CD013461,CD013461 v. 2.0 Behavioural activation therapy for depression in adults with non-communicable diseases
1789,CD013462,CD013462 v. 1.19 Duct-to-mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative panc
1790,CD013465,CD013465 v. 2.0 Individualized versus standard diet fortification for growth and development in preterm infants rece
1791,CD013479,CD013479 v. 1.92 Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention o
1792,CD013484,CD013484 v. 1.120 Tocilizumab for giant cell arteritis
1793,CD013487,CD013487 v. 3.0 Multiple drug combinations of bortezomib lenalidomide and thalidomide for first-line treatment in 
1794,CD013495,CD013495 v. 1.470 Approaches for discontinuation versus continuation of long-term antidepressant use for depressive an
1795,CD013496,CD013496 v. 2.2 Intermittent fasting for the prevention of cardiovascular disease
1796,CD013498,CD013498 v. 2.0 (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus
1797,CD013501,CD013501 v. 1.61 Vegan dietary pattern for the primary and secondary prevention of cardiovascular diseases
1798,CD013504,CD013504 v. 2.1 Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhyt
1799,CD013505,CD013505 v. 1.0 Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome
1800,CD013506,CD013506 v. 1.39 Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease
1801,CD013512,CD013512 v. 3.3 Transepithelial versus epithelium-off corneal crosslinking for progressive keratoconus
1802,CD013514,CD013514 v. 2.8 Ginkgo biloba for tinnitus
1803,CD013515,CD013515 v. 2.9 Psychological therapies for temporomandibular disorders (TMDs)
1804,CD013516,CD013516 v. 2.0 Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in
1805,CD013519,CD013519 v. 1.76 Acupuncture for treating overactive bladder in adults
1806,CD013527,CD013527 v. 1.150 Physical activity and education about physical activity for chronic musculoskeletal pain in children
1807,CD013529,CD013529 v. 1.72 Interventions for treating iron deficiency anaemia in inflammatory bowel disease
1808,CD013538,CD013538 v. 1.16 Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer
1809,CD013544,CD013544 v. 4.1 Interventions for promoting physical activity in people with neuromuscular disease
1810,CD013558,CD013558 v. 2.15 Oxygenation during the apnoeic phase preceding intubation in adults in prehospital emergency depart
1811,CD013560,CD013560 v. 1.148 Antidepressant treatment for postnatal depression
1812,CD013569,CD013569 v. 2.13 Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chro
1813,CD013572,CD013572 v. 2.10 Multi-domain interventions for the prevention of dementia and cognitive decline
1814,CD013573,CD013573 v. 1.37 Pharmacological interventions for asymptomatic carotid stenosis
1815,CD013577,CD013577 v. 1.0 Epidural corticosteroid injections for lumbosacral radicular pain
1816,CD013579,CD013579 v. 2.3 Treatment options for progression or recurrence of glioblastoma a network meta-analysis
1817,CD013585,CD013585 v. 1.79 Ultrasound guidance for arterial (other than femoral) catheterisation in adults
1818,CD013587,CD013587 v. 2.53 Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19
1819,CD013594,CD013594 v. 1.0 Treating progressive disseminated histoplasmosis in people living with HIV
1820,CD013600,CD013600 v. 4.35 Convalescent plasma for people with COVID-19 a living systematic review
1821,CD013601,CD013601 v. 2.5 Carnitine supplements for people with chronic kidney disease requiring dialysis
1822,CD013609,CD013609 v. 2.10 Interventions for treating supracondylar elbow fractures in children
1823,CD013610,CD013610 v. 2.14 Interventions for improving adherence to airway clearance treatment and exercise in people with cyst
1824,CD013611,CD013611 v. 1.7 Vedolizumab for induction and maintenance of remission in Crohn's disease
1825,CD013620,CD013620 v. 2.1 Alternating pressure (active) air surfaces for preventing pressure ulcers
1826,CD013621,CD013621 v. 2.0 Foam surfaces for preventing pressure ulcers
1827,CD013630,CD013630 v. 2.0 Intraoperative imaging technology to maximise extent of resection for glioma a network meta-analysi
1828,CD013633,CD013633 v. 1.0 Strategies for optimising antenatal corticosteroid administration for women with anticipated preterm
1829,CD013636,CD013636 v. 2.0 Effects of total fat intake on body fatness in adults
1830,CD013656,CD013656 v. 2.11 Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperpla
1831,CD013662,CD013662 v. 1.40 Prehabilitation exercise therapy before elective abdominal aortic aneurysm repair
1832,CD013663,CD013663 v. 1.0 Mechanical and surgical interventions for treating primary postpartum haemorrhage
1833,CD013667,CD013667 v. 2.220 Interventions for self-harm in children and adolescents
1834,CD013668,CD013668 v. 1.380 Psychosocial interventions for self-harm in adults
1835,CD013674,CD013674 v. 2.12 New generation antidepressants for depression in children and adolescents a network meta-analysis
1836,CD013679,CD013679 v. 1.0 Targeted client communication via mobile devices for improving maternal neonatal and child health
1837,CD013680,CD013680 v. 1.0 Targeted client communication via mobile devices for improving sexual and reproductive health
1838,CD013683,CD013683 v. 1.22 Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric s
1839,CD013684,CD013684 v. 1.7 Psychological interventions to foster resilience in healthcare students
1840,CD013686,CD013686 v. 3.0 Interventions to reduce contaminated aerosols produced during dental procedures for preventing infec
1841,CD013690,CD013690 v. 11.6 Type of anaesthesia for acute ischaemic stroke endovascular treatment
1842,CD013696,CD013696 v. 2.3 Mindfulness for smoking cessation
1843,CD013700,CD013700 v. 2.11 Treatment for gastrointestinal and pancreatic neuroendocrine tumours a network meta-analysis
1844,CD013710,CD013710 v. 2.16 Negative pressure wound therapy for managing the open abdomen in non-trauma patients
1845,CD013712,CD013712 v. 2.12 Trunk training following stroke
1846,CD013733,CD013733 v. 2.10 Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis
1847,CD013750,CD013750 v. 2.0 Platinum-containing regimens for triple-negative metastatic breast cancer
1848,CD013751,CD013751 v. 2.9 Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
1849,CD013756,CD013756 v. 3.3 Implanted spinal neuromodulation interventions for chronic pain in adults
1850,CD013766,CD013766 v. 8.6 Psychological interventions for improving adherence to inhaled therapies in people with cystic fibro
1851,CD013776,CD013776 v. 2.11 Blue versus white light for transurethral resection of non-muscle invasive bladder cancer
1852,CD013778,CD013778 v. 2.14 Inspiratory muscle training with or without concomitant pulmonary rehabilitation for chronic obstr
1853,CD013814,CD013814 v. 1.3 Acupuncture for chronic nonspecific low back pain
1854,CD013817,CD013817 v. 2.10 Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension
1855,CD013820,CD013820 v. 12.6 Social network interventions to support cardiac rehabilitation and secondary prevention in the manag
1856,CD013825,CD013825 v. 2.13 SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19
1857,CD013826,CD013826 v. 2.9 Preprocedural mouth rinses for preventing transmission of infectious diseases through aerosols in de
1858,CD013829,CD013829 v. 4.4 Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality
1859,CD013845,CD013845 v. 2.25 Memantine for autism spectrum disorder
1860,CD013862,CD013862 v. 1.16 Healthy eating interventions delivered in early childhood education and care settings for improving 
1861,CD013863,CD013863 v. 1.10 Psychological therapies delivered remotely for the management of chronic pain (excluding headache) i
1862,CD013871,CD013871 v. 3.6 Fecal microbiota transplantation for the treatment of recurrent iClostridioides difficilei (i
1863,CD013873,CD013873 v. 2.7 Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity
1864,CD013877,CD013877 v. 4.3 Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction
1865,CD014201,CD014201 v. 1.13 Clotting factor concentrates for preventing bleeding and bleeding-related complications in previousl
1866,CD014257,CD014257 v. 8.0 Probiotics for treatment of chronic constipation in children
1867,CD014328,CD014328 v. 1.5 Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal t
1868,CD014384,CD014384 v. 1.12 Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
1869,CD014484,CD014484 v. 1.7 Low-dose oral misoprostol for induction of labour
1870,CD014513,CD014513 v. 0.33 Quality improvement strategies for diabetes careEffects on outcomes for adults living with diabete
1871,CD014592,CD014592 v. 1.10 Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women
1872,CD014605,CD014605 v. 3.9 Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis
1873,CD014606,CD014606 v. 1.10 Digital technology for early identification of exacerbations in people with cystic fibrosis
1874,CD014638,CD014638 v. 1.10 Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving a
1875,CD014641,CD014641 v. 1.15 Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in
1876,CD014682,CD014682 v. 1.15 Antidepressants for pain management in adults with chronic pain a network meta-analysis
1877,CD014739,CD014739 v. 2.5 Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agen
1878,CD014758,CD014758 v. 1.15 Interventions for myopia control in children a living systematic review and network meta-analysis
1879,CD014788,CD014788 v. 1.17 Gonadotropin-releasing hormone analogues for endometriosis
1880,CD014789,CD014789 v. 1.35 Spinal cord stimulation for low back pain
1881,CD014799,CD014799 v. 1.14 Conservative interventions for managing urinary incontinence after prostate surgery
1882,CD014806,CD014806 v. 1.14 Sucrose analgesia for heel-lance procedures in neonates
1883,CD014816,CD014816 v. 1.18 Exercise as adjunctive therapy for systemic lupus erythematosus
1884,CD014821,CD014821 v. 4.6 Remote care through telehealth for people with inflammatory bowel disease
1885,CD014874,CD014874 v. 1.22 Interventions from pregnancy to two years after birth for parents experiencing complex post-traumati
1886,CD014876,CD014876 v. 2.5 Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates
1887,CD014884,CD014884 v. 2.6 Intravenous immunoglobulin for the treatment of Kawasaki disease
1888,CD014887,CD014887 v. 1.27 Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle in
1889,CD014890,CD014890 v. 1.26 Vocabulary interventions for second language (L2) learners up to six years of age
1890,CD014989,CD014989 v. 5.5 Surgical decompression for malignant cerebral oedema after ischaemic stroke
1891,CD015016,CD015016 v. 2.15 Systemic opioid regimens for postoperative pain in neonates
1892,CD015017,CD015017 v. 6.4 Ivermectin for preventing and treating COVID-19
1893,CD015017,CD015017 v. 6.7 Ivermectin for preventing and treating COVID-19
1894,CD015031,CD015031 v. 1.21 Pars plana vitrectomy with internal limiting membrane flap versus pars plana vitrectomy with convent
1895,CD015045,CD015045 v. 1.19 Colchicine for the treatment of COVID-19
1896,CD015056,CD015056 v. 1.19 Opioids for procedural pain in neonates
1897,CD015078,CD015078 v. 0.5 Antiplatelet agents for the treatment of adults with COVID-19
1898,CD015091,CD015091 v. 1.7 Topical ophthalmic anesthetics for corneal abrasions
1899,CD015102,CD015102 v. 1.24 Prophylactic anticoagulants for non-hospitalised people with COVID-19
1900,CD015125,CD015125 v. 10.0 Inhaled corticosteroids for the treatment of COVID-19
1901,CD015133,CD015133 v. 1.12 Prebiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants
1902,CD015148,CD015148 v. 1.11 Local corticosteroid injection versus placebo for carpal tunnel syndrome
1903,CD015167,CD015167 v. 1.13 Hyperimmune immunoglobulin for people with COVID-19
1904,CD015171,CD015171 v. 1.4 Systemic pharmacological interventions for Mnires disease
1905,CD015179,CD015179 v. 1.7 Non-opioid analgesics for procedural pain in neonates
1906,CD015187,CD015187 v. 1.5 Pharmacological interventions for prophylaxis of vestibular migraine
1907,CD015207,CD015207 v. 0.4 Replacing salt with low-sodium salt substitutes (LSSS) for cardiovascular health in adults children
1908,CD015209,CD015209 v. 1.9 Janus kinase inhibitors for the treatment of COVID-19
1909,CD015244,CD015244 v. 1.5 Lifestyle and dietary interventions for Mnires disease
1910,CD015246,CD015246 v. 1.4 Intratympanic gentamicin for Mnires disease
1911,CD015249,CD015249 v. 1.3 Surgical interventions for Mnires disease
1912,CD015333,CD015333 v. 1.6 Non-pharmacological interventions for persistent postural-perceptual dizziness (PPPD)
1913,CD015391,CD015391 v. 1.9 Fluvoxamine for the treatment of COVID-19
1914,CD015422,CD015422 v. 1.29 Topical repellents for malaria prevention
